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Abbreviations 
Akt v-Akt murine thymoma viral oncogene 
AP-1 Activator protein 1 
APE   Alanine, proline, glutamate 
Aβ  Amyloid-β peptide 
Bax Bcl2-associated protein 
Bcl2 B-cell lymphoma 2 
Bim Bcl2 interacting mediator 
BMP-6 Bone morphogenetic protein 6 
B-Raf  v-RAF murine sarcoma viral oncogene homolog B 
BrdU   Bromodeoxyuridine 
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Cdc42  Cell division cell cycle 42 
CDK  Cyclin-dependent kinase 
CDKI  Cyclin-dependent kinase inhibitor 
cDNA  Complementary deoxyribonucleic acid 
CHO  Chinese hamster ovary 
CK  Cytokeratin 
CRIB    Cdc42/Rac interactive binding motif 
DEPC  Diethyl pyrocarbonate 
DFG   Aspartate, phenylalanine, glycine 
DLK   Dual-leucine-zipper-bearing kinase 
DMEM  Dulbecco’s modified Eagle’s medium 
DNA  Deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
DTT  Dithiothreitol 
E2   17β-estradiol 
ECL   Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
EGF   Epidermal growth factor 
EGFR  EGF receptor 
ER-  Estrogen receptor-negative 
ERK  Extracellular signal-regulated kinase 
FBS  Fetal bovine serum 
FZD10  Frizzled homologue 10 
G17  Gastrin-17 
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GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GCK  Germinal center kinase 
GDP  Guanosine diphosphate 
Gly  Glycine 
GnRH-a  Gonadotropin releasing hormone analogs 
GPCR   G protein-coupled receptor  
GRP  Glycine-rich protein 
GSK-3β  Glycogen synthase kinase-3 beta 
GTP  Guanosine triphosphate 
GTPase  Guanosine triphosphatase 
HEK293  Human embryonic kidney 293 
HNSCC  Head and neck squamous cancer 
HPK  Hematopoietic kinase 
H-Ras  Harvey rat sarcoma virus oncogene 
HRP  Horseradish Peroxidase  
Hsp90  Heat-shock protein 90 
IgG  Immunoglobulin G 
IKB  Inhibitor of NF-KB 
IKC   IĸB kinase complex  
IKK   IĸB kinase  
IL-1  Interleukin-1 
JIP  JNK-interacting protein 
JNK  c-Jun N-terminal kinase 
KIF  Kinesin superfamily protein 
K-Ras  Kirsten rat sarcoma virus oncogene  
LEF1  Lymphoid enhancer-binding factor-1 
LZK  Leucine zipper-bearing kinase 
MAPK  Mitogen-activated protein kinase 
MEK  MAPK/ERK kinase 
MEKK   Erk kinase kinase (=MAP3K=MAPKKK) 
MKK  Mitogen-activated protein kinase 
MLK3  Mixed-lineage kinase 3 
MMP7  Metalloproteinase 7 
mRNA  Messenger ribonucleic acid 
MSI  Microsatellite instability 
NAD+  Nicotinamide adenine dinucleotide  
NADH  Reduced nicotinamide adenine dinucleotide 
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NADPH  Reduced nicotinamide adenine dinucleotide phosphate 
NF  Neurofibromatosis 
NF-kB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NGF  Nerve growth factor  
NIH3T3   Mouse embryo fibroblast cell line 
NIMA  Never-in-mitosis in Aspergillus nidulans 
NMDA  N-methyl-D-aspartic acid 
P/S/T  Proline/Serine/Threonine 
p63RhoGEF  p63 Rho guanosine nucleotide exchange factor 
PARP  Protein poly (ADP-ribose) polymerase 
PBS  Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDPKs  Proline-directed protein kinases 
Phospho  Phosphorylated 
PI   Propidium iodide 
PI3K  Phosphatidylinositol 3-kinase 
Pin1  Peptidylprolyl cis/trans isomerase, NIMA-interacting 1 
POSH  Plenty of SH3s 
PR-  Progesterone receptor-negative 
PRDs-   Proline-recognition domains 
PS   Penicillin–streptomycin 
PTEN  Phosphatase and tensin homologue deleted on chromosome ten 
PTK1  Protein-tyrosine kinase 1 
Raf-1  v-raf-1 murine leukemia viral oncogene homolog 1 
Rho  Ras homologue gene 
RNA  Ribonucleic acid 
RNAi  RNA interference 
ROCK   Rho-associated coiled-coil forming kinase  
ROS   Reactive oxygen species 
RT-PCR   Reverse-transcriptase PCR 
SCG   Superior cervical ganglion 
SH3   Src homology 3 
siRNA  Small interfering RNA 
Slpr  Slipper 
SPRK   SH3-containing proline-rich protein kinase 
Taq  Thermus aquaticus 
TBE   Tris-borate-EDTA 
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TGF-β  Transforming growth factor-beta 
Tm  Melting temperature 
TNF-α  Tumour necrosis factor-alpha 
UV  Ultraviolet 
WNT  Wingless and INT1 
WT  Wild-type 
ZAK   Zipper-sterile-α-motif kinase 
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Resumo 
A proteína mixed-lineage kinase 3 (MLK3) é uma cinase de serina/treonina vastamente 
expressa que está envolvida em diferentes funções fisiológicas como proliferação, 
apoptose, sobrevivência e migração celular. Ao responder a mitogénios e estímulos de 
stress regula a sinalização das MAPK através da activação das vias da ERK, JNK e 
p38. O seu domínio cinase é crucial para fosforilar e consequentemente activar 
moléculas alvo. Contudo, a activação da MLK3 nem sempre é requerida para a 
modulação de algumas funções por ela induzidas. A MLK3 pode ainda funcionar como 
proteína scaffold, ligando diferentes vias de sinalização. 
 
Mutações na MLK3 foram descritas, pela primeira vez, em 2010 pelo nosso grupo. 
Nesse mesmo trabalho, foi demonstrado que mutações missense na MLK3 possuíam 
potencial transformante e tumorigénico. Duas dessas mutações (P252H e R799C) 
mostraram um comportamento invasivo. Tendo em conta estas informações nós 
estabelecemos linhas celulares (HEK293) que expressam de uma forma estável estas 
mutações para assim identificar os efeitos celulares a elas associados e avaliar quais 
os alvos moleculares dependentes desses dois mutantes da MLK3. Verificámos que a 
mutação no domínio cinase da MLK3 (P252H) confere propriedades diferentes quando 
comparada com a mutação localizada no domínio rico em prolina. A mutação P252H 
parece induzir uma maior migração celular, enquanto a mutação R799C parece 
interferir com a diferenciação celular. Além disso, nós verificámos que ambas as 
mutações regulam a via do WNT de maneira distinta, seja através da activação da via 
canónica ou da não canónica. Em resumo, o trabalho descrito nesta tese mostra que 
duas das mutações na MLK3, previamente descritas, interferem com vias de 
sinalização cruciais do desenvolvimento colorectal e neste sentido contribuem para a 
tumorigénese colorectal. 
 
 
Palavras-chave: MLK3, mutações; HEK293 
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Abstract 
Mixed-lineage kinase 3 (MLK3) is a serine/threonine kinase widely expressed and 
involved in different physiological functions, such as proliferation, apoptosis, cell 
survival and cell migration. Responding to mitogens and stress stimuli it regulates 
MAPK signalling through activation of ERK, JNK, p38 pathways. Its kinase domain is 
crucial to phosphorylate and thus activate downstream targets. However, MLK3 
activation is not always required to MLK3-induced modulation of some cellular 
functions. MLK3 may indeed function as a scaffold protein, linking different signalling 
pathways.  
 
MLK3 mutations were reported, for the first time, in 2010 by our group. Missense MLK3 
mutations were found to be able to harbour transforming and tumourigenic potential. 
Two of the mutations (P252H and R799C) were found to show an invasive behaviour. 
Taking this data into account we generated HEK293 stable cell lines harbouring these 
mutations in order to identify associated cellular effects and evaluate which molecular 
targets were dependent of these two MLK3 mutants. We found that a mutation in MLK3 
kinase domain (P252H) confers different properties when compared to a one localized 
in the proline-rich domain. P252H mutation seems to induce increased cell migration, 
while R799C seems to interfere with cell differentiation. Furthermore, we verified that 
both mutations regulate the WNT pathway in distinct manner, either through the 
activation of the canonical or non-canonical pathway. In summary, we showed that two 
of the MLK3 mutations previously described interfere with crucial pathways of 
colorectal development and in this way contribute to colorectal tumourigenesis.  
 13 
1 Chapter 1       Introduction 
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1.1 Mixed-lineage kinase 3 (MLK3) 
MLK3, also designated MEKK11, SPRK or PTK1, is a mitogen activated protein kinase 
kinase kinase (MAP3K) involved in the cellular response to mitogen and stress stimuli, 
through activation of extracellular signal-regulated kinase (ERK), p38 and c-Jun N-
terminal kinase (JNK). MLK3 gene is mapped at 11q13.1-q13.3 and encodes a 
cytoplasmatic protein of 847 aminoacids, with 95KDa [1, 2]. Although this protein 
presents a markedly perinuclear along with punctate, vesicular patterns and limited 
diffuse cytosolic pattern its cellular localization also changes during cell cycle phases 
as will be further described [3, 4].  
 
MLK3 belongs to the MLK family, which has an important role in response to 
environmental stress, inflammatory cytokines and growth factor and whose members 
are activated by upstream G-proteins including Cdc42 and Rac1 [5]. MLKs were first 
characterized as dual specificity kinases, i.e. kinases with both serine/threonine and 
tyrosine kinase activity [6]. However, tyrosine kinase activity has never been reported 
[7]. In mammals MLKs cluster is composed of seven proteins divided into three 
subgroups, according to their structure similarities: MLKs (MLK1 - 4), the dual-leucine-
zipper-bearing kinases (DLKs – DLK and LZK) and the zipper-sterile-α-motif kinase 
(ZAK) [8]. Some of these proteins are tissue-specific, while MLK3 is ubiquitously 
expressed, either in fetal or adult tissue [1, 9]. 
1.1.1 MLK3 structure organization 
MLK3 shares most of its structure features with MLKs proteins subgroup (MLK1-4) [9]. 
MLK3 structure (Figure 1) is composed of a NH2-terminal glycine-rich region, an 
amino-terminal Src homology 3 (SH3) domain, a kinase catalytic domain, two leucine 
zippers domain, a Cdc42/Rac interactive binding (CRIB) motif and a COOH-terminal 
proline/serine/threonine-rich region [6, 9, 10]. These domains will be described with 
more detail.  
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Figure 1- Schematic representation of MLK3 protein structure. In this figure are 
represented the domains above mentioned and the position number of the initial and final 
aminoacid for each domain [11]. 
 
Glycine-rich region. Glycine-rich proteins (GRPs) are characterized by the presence of 
Glycine-rich domains that are arranged in (Gly)n-X repetitions. This type of domain was 
first discovered and well characterized in proteins from plants, but nowadays proteins 
with this kind of repetition are reported in a wide variety of organisms, from 
cyanobacterias to animals (reviewed in [12]). Thus, depending on the context GRPs 
exert different physiological roles, such as signal transduction, stress response, 
transcriptional regulation and development [13]. Contrarily to other members of MLK 
subfamily, MLK3 harbours a glycine-rich region, whose longest stretch has 9 
continuous glycine residues [1, 9]. However, the biological relevance of this region in 
MLK3 remains unknown. 
 
SH3 domain. SH3 domain makes part of the superfamily of proline-recognition domains 
(PRDs) and is one of the most abundant PRDs in vertebrates. SH3 domain is not quite 
selective, as it binds to various peptides and protein ligands (reviewed in [14]). In MLK3 
this domain contains three extremely conserved aromatic residues (Tyr52, Trp83 and 
Tyr99). Specific intramolecular interactions may occur between a domain and its binding 
sequence when they coexist in a single polypeptide chain and this is what happens in 
MLK3 [10]. The SH3 domain of MLK3 promotes an autoinibitory interaction that will be 
described in chapter Regulation through intramolecular interactions. As SH3 domains 
commonly bind to proline-rich regions, it is possible that in MLK3 it also binds to the 
large COOH-terminal proline-rich tail of this protein 
 
Kinase domain. Protein kinases harbour an ATP-binding region within its kinase 
domain, also known by catalytic domain [15]. In MLK3 ATP-binding site compromises a 
region from aminoacid 123 to 131. The kinase domain usually folds into a two-lobed 
structure, composed of different subdomains. Between the two lobes there is a highly 
conserved loop and ATP sits beneath it. This loop, also designated as the “activation 
loop”, has typically 20–30 residues in length and is crucial to substrate recognition and 
kinase activation [15]. Many kinases are phosphorylated (either by itself 
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(autophosphorylation) or by other kinases) in this centrally located loop, localized 
between the conserved motifs DFG (Asp184PheGly – located at the base of the loop) 
of subdomain VII and APE (Ala206, Pro207 and Glu208) of subdomain VIII [16]. In 
MLK3, the activation loop was also proved to be crucial for MLK3 autophosphorylation 
and its subsequent activation [17]. 
 
The construct of a kinase-deficient mutant of MLK3, through replacement of lysine 144 
(which is a highly conserved residue among catalytic domains of most protein kinases 
and is known to be critical for binding of ATP) for an arginine residue is commonly used 
to study the role of MLK3 kinase domain [5, 18]. One of these studies describes a 
drastic reduction on JNK activation when cells expressing this mutant are stimulated by 
the GTPases Cdc42 and Rac1 [5]. 
 
Leucine zippers. The leucine-rich domains mediate protein dimerization or 
oligomerization. In MLK subfamily, MLK1-MLK4 share about 70% sequence identity [9]. 
The predicted helix-turn-helix conformation for double zipper region allow for an 
interaction between the two zippers of one MLK3 molecule to form a uniquely folded 
zipper-turn-zipper domain [6].  
 
CRIB motif. The CRIB motif was first termed like that because it confers binding to the 
Cdc42 and/or Rac GTPases [19]. It contains eight core amino acids with the sequence 
I-S-X-P-(X)2–4-F-X-H-X-X-H-V-G and is not exclusive of kinases. Like other kinases, 
MLK3 significantly binds to Cdc42-GTP, but not to Cdc42-GDP. It also binds to Rac, 
but to a less extent than to Cdc42, either to its wild type or constitutively active form 
[19].  
 
Proline/Serine/Threonine-rich region. This is the less conserved region between MLK 
family members and thus it might be associated to different regulatory functions 
(reviewed in [9]). In COOH-terminal of MLK3, proline residues contribute 24% of the 
total number of amino acids in that region. They present a uniform distribution along 
the COOH-terminal region with stretches no longer than three residues [1]. Proline-rich 
region present in MLK3 could bind to the SH3 domain either in MLK3 itself or in other 
proteins [1]. Although some phosphrylation sites were already identified in MLK3 
proline/serine/threonine-rich region [20] (Figure 4), specific regulatory functions 
conferred by this domain to each of MLK kinases remain unknown.  
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1.1.2 Regulation of MLK3 activity 
Protein kinases are involved in many critical physiological roles and thus the regulation 
of its protein activity is fundamental. The mechanisms for protein kinases regulation 
falls into two categories: regulation by pseudosubstrate autoinhibitory domains, and 
remodelling of the catalytic core in response to phosphorylation and/or protein/protein 
interactions [21]. 
1.1.2.1 Regulation through intramolecular interactions 
SH3-mediated autoinhibition. Through a series of mapping experiments it was 
identified a region in MLK3 with which the SH3 domain of MLK3 itself interacts: a 
sequence located between zipper and CRIB motifs, that contains a single proline 
residue at position 469 (which is conserved in MLK1, 2, 3 and in slpr) (Figure 2) [9, 10]. 
Replacement of this proline by an alanine increases the catalytic activity of MLK3, 
which is in agreement with the autoinhibition of MLK3 by an SH3-mediated 
intramolecular interaction. 
 
Figure 2 - Representation of the SH3-mediated intramolecular interaction that leads to 
MLK3 autoinhibition [9]. 
Leucine zipper homodimerization. Dimerization of MLK3 via the leucine-zippers 
domain and subsequent autophosporylation was shown to be critical for proper 
interaction with and phosphorylation of downstream targets [22, 23]. 
1.1.2.2 Regulation through phosphorylation 
MLK3 may be phosphorylated by itself or other kinases. Two residues seem to be 
critical for MLK3 autophosphorylation, thus to its efficient activity: Thr277 (which is 
conserved in MLK1 and MLK2) and Ser281, that is conserved among all MLK family 
members [17]. The commercial available antibodies for phospho-MLK3 were designed 
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to only recognize these to residues. When any of these residues are mutated to 
alanine, MLK3 autophosphorylation levels alter, namely in mutant Thr277 that displays a 
significantly reduced MLK3 autophosphorylation activity [17]. However, when Thr277 
and Ser281 are mutated to negatively charged glutamic acid, mimicking phosphorylated 
serine/threonine residues, they retain MLK3 kinase activity, indicating that they serve 
as MLK3 (auto)phosphorylation sites [17]. Taken together these data and the previous 
one about MLK3 dimerization, we can predict that activation of MLK3 requires at an 
initial step an induced-homodimerization, which then leads to protein 
autophosphorylation and subsequent activation [17]. 
 
Additional in vivo MLK3 phosphorylation sites were identified through mass 
spectrometry techniques: Arg37, Ser524, Ser555, Ser556, Ser654, Ser705, Ser724, Ser727, 
Ser740, Ser758, Ser770 and Ser793 (Figure 4) [20]. Due to technical limitations this study 
could not possible identify very stable MLK3 phosphorylation sites. Of the twelve sites 
identified, eight are localized in the COOH-terminal region of MLK3 and three are in the 
region immediately following the CRIB domain (including the two Cdc42-inducible sites 
Ser555 and Ser556) [20]. As most of MLK3 phosphorylation sites are followed by a 
proline residue and proline-directed protein kinases (PDPKs) phosphorylate Ser/Thr 
residues that are immediately followed by a proline residue, it is suggested that MLK3 
could be a target of this type of kinases, which include for instance the glycogen 
synthase kinase-3 (GSK-3) that is a protein involved in different pathways, namely in 
wingless and INT1 (WNT) signalling and phosphatidylinositol 3-kinase (PI3K) pathway  
[20, 24]. Curiously, the beta isoform of GSK-3 was found to phosphorylate MLK3 in 
residues Ser789 and Ser793 [25].  
 
Binding to RhoGTPases. In MLK3 the binding of Cdc42 or Rac, both in their GTP 
form, to CRIB motif competes with SH3-mediated autoinhibition, inducing a 
conformational change and thereby allowing the activation of MLK3 kinase activity 
(Figure 3) [3, 9]. 
 19 
 
Figure 3 - Inactivation of SH3-induced autoinhibition in MLK3, through binding of Cdc42-
GTP to CRIB motif [9]. 
Cdc42-GTP binding disrupts MLK3 autoinhibition, and then induces MLK3 dimerization 
and subsequent phosphorylation within the activation loop. However, this binding does 
not lead to the immediately fully activation of MLK3 [3]. Besides an intact CRIB motif to 
a correct Cdc42-GTP association with MLK3, which leads to its partial activation, the 
Cdc42 geranylgeranylation (which is a subtype of lipid posttranslational modification 
essential for proteins localization to cell membrane and hence for their biological 
function [26]) is also required to Cdc42 and MLK3 co-localization at plasma membrane 
and consequently for fully MLK3 activation and signalling to JNK [3]. 
Binding to other upstream molecules. MLK3 interacts with germinal center kinase 
(GCK) and hematopoietic kinase (HPK) which are two yeast Ste20 homologues that 
directly phosphorylate MLK3 and promote its activation [27, 28] Ser281 residue, located 
in MLK3 activation loop, was identified as the HPK1-phosphorylation site [17].  
 
Two important triggers of cell death were also reported to act upstream MLK3: tumour 
necrosis factor-alpha (TNF-α) and ceramide, which is a lipid molecule that makes up 
sphingomyelin, one of the major lipids in the lipid bilayer. TNF-α and ceramide-induced 
MLK3 activation leads to JNK pathway activation, without affecting ERK and p38 
pathways [29]. In MLK3-deficient fibroblasts it was observed a suppression of TNF-
stimulated JNK activation and so MLK3 requirement to JNK activation appears to be 
selective to TNF [30].  
Besides the mentioned MLK3 upstream activators there are two more that regulate in 
opposite ways its activity: Akt and GSK-3β [25, 31]. Akt is able to suppress MLK3 
activity by phosphorylating it in Ser674, what leads to inhibition of MKK7 and JNK 
activities and consequently promotes cell survival [31]. GSK-3β phosphorylates MLK3 
in its C-terminal, more precisely in Ser789 and Ser793 residues, leading to MLK3 
activation [25]. 
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Taking into account all data about the yet identified residues that might be 
phosphorylated in MLK3, a more detailed schematic representation of its structure is 
represented (Figure 4). 
 
 
 
Figure 4 - Localization of the already discovered MLK3 (auto)phosphorylation sites in 
MLK3 schematic structure. Ser
281 
is phosphorylated by HPK1, Ser
555
 and Ser
556
 by Cdc42, 
Ser
674
 by Akt, Ser
789
 and Ser
793
 by GSK3β. [17, 20, 25, 28].  
Binding to JNK. Although JNK is a downstream target of MKL3, it may also controls 
MLK3 levels, by phosphorylating and activating it, through a positive-feedback loop 
[32]. Thus, when JNK activity is diminished there is a decrease in 
hyperphosphorylated, active MLK3 and the opposite also happens. JNK inhibition leads 
to a change in MLK3 cellular distribution, i.e. MLK3 shifts from a Triton-soluble form to 
a Triton-insoluble fraction, which largely lacks the association with heat shock protein 
Hsp90 and co-chaperone p50cdc37 and thus inactivates MLK3, but this effect can be 
reversed [9, 33]. Many kinases that interact with Hsp90/p50cdc37 are stabilized by this 
association [33]. A final model suggests that MLK3 is first phosphorylated by JNK at 
the COOH-terminal and then a phosphatase may target the same sites. So, MLK3 
cellular levels are, at least in part, regulated by the balance between these two 
activities [34]. 
1.1.3 MLK3 role in different physiological functions 
MLK3 directly interacts with many different molecules (Figure 5). Some are upstream 
activators that were already mentioned. Like others MLK family members, MLK3 also 
respond to some stimuli that causes cellular stress, activating JNK and p38 pathways 
by directly phosphorylating and activating MKK4/MKK7 (JNK kinases) and 
MKK3/MKK6 (p38 MAP kinases), respectively [7, 9, 35, 36]. Some authors found that 
MLK3 silencing, using MLK3 RNAi, suppressed mitogen and cytokine activation of 
JNK, ERK and p38 [37]. Thus, depending on the cellular context, MLK3 has been 
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implicated in different cellular responses such as apoptosis, proliferation, migration and 
survival. As will be described along this chapter, MLK3 kinase activity is essential to 
activation of downstream targets, but its scaffold property is also important. 
MLK3
B-Raf/Raf-1
NF2
Hsp90/…dc37
KIF
Pin1
Rac1-GTP RhoG-GTP
Map3k12
Cdc42-GTP
MEK1
golgin-160
CNK1
JIP
IKK
phAkt
PSD95
POSH
HPK1
GCK
MEK3
MEK4,7
GSK-3β
 
Figure 5 - Summary of proteins with which MLK3 interacts. (udapted from UCSD- Nature 
Molecule Page. doi:10.1038/mp.a001551.01. and [25]) 
1.1.3.1 MLK3 role in cell proliferation 
The fact that MLK3 silencing prevented serum-stimulated cell proliferation suggests a 
possible role for MLK3 in ERK activation [37]. As widely known ERK proteins are 
essential for cell proliferation induced by mitogens [38]. 
 
MLK3 has the ability to regulate either positive or negatively the ERK pathway, 
depending on the stimulus and duration of the exposure. Some extracellular factors 
induce sustained activation of MLK3 and JNK pathway leading to attenuation of ERK 
pathway activation, which implicates Jun transcription, while MLK3 short phase 
activation may lead to the opposite effect. ERK activation occurs through MLK3-
mediated phosphorylation and consequent activation of mitogen-activated protein 
kinase 1 (MEK1) [39]. 
 
In 2004, MLK3 was implicated in the regulation B-Raf-Raf-1 complex (Figure 6) [37, 
40]. Both B-Raf and Raf-1 undergo Ras-dependent phosphorylation, but formation of a 
B-Raf–Raf-1 complex in vivo enables B-Raf to transactivate Raf-1 [41]. MLK3 is 
required for B-Raf phosphorylation in an indirect manner, by maintaining the integrity of 
the complex. The levels of the MLK3-B-Raf-Raf-1 complex are then regulated by the 
tumour suppressor merlin (protein encoded by neurofibromatosis 2 gene - NF2). It 
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interacts with MLK3, disrupting the complex integrity. Therefore, merlin protein is able 
to decrease ERK activation and negatively interferes with other MLK3 associated 
pathways, like JNK pathway [40]. 
 
 
Figure 6  – MLK3 interactions in mitogen-activated protein kinases (MAPK) signalling 
[42]. 
1.1.3.1.1 MLK3 may contribute to microtubule instability during mitosis 
Interestingly, MLK3 was found to have homology with C-terminal extension of NIMA, a 
serine/threonine mitotic kinase, which is present in the filamentous fungus Aspergillus 
nidulans [4]. This kinase is essential for correct G2/M transition and was found to 
interact with the human protein Pin 1, that is a peptydil-prolyl cis/trans isomerase. Pin 1 
ability to regulate mitosis is presumably related to this interaction [43, 44]. MLK3 was 
also found to interact with the peptydil isomerase Pin1, being its Pin1-binding 
properties similar to those of NIMA [4].  
 
Although MLK3 protein levels remain constant throughout the cell cycle, there is a 
hyperphosphorylation and an increase in kinase activity (in similar levels to NIMA), both 
in G2/M. MLK3 distribution changes from interphase to cytokinesis and was found to be 
dependent on microtubule organization. During interphase MLK3 staining appears as 
numerous foci proximal to the nucleus, which becomes more intense around 
centrosomes in prophase. In metaphase and anaphase MLK3 appears to be uniformly 
distributed through the cell. However, after cytokenesis the centrosome-associated 
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sprinkle distribution is reestablished [4]. Curiously, the subcellular localization of both 
NIMA and MLK3 is associated with centrosome-nucleated microtubules as well as with 
centrosome-itself. Overexpression of wild-type MLK3 leads to the disruption of 
microtubule organization in interphase and mitotic cells, what was also observed for 
NIMA overexpression [4]. 
 
Despite similarities between NIMA and MLK3, MLK3 does not trigger a cell cycle arrest 
at G2 as NIMA does [4]. Taking together NIMA and MLK3 similarities, and despite 
MLK3-Pin1 interaction is not well known, we can predict an important role for MLK3 in 
mitosis. 
1.1.3.2 Role of MLK3 in JNK-mediated cell death or survival 
Characterization of MLK3 physiological function has primarily evolved around its role in 
regulating the activity of JNK, which, in turn, mediates the apoptosis of different cell 
types, particularly neurons. Thus, MLK3 has been suggested as a pharmacological 
target for treatment of neurodegenerative disorders such as Parkinson´s and 
Alzheimer´s diseases, which are associated with dysregulation of apoptosis [45-47]. 
Some of these studies are reviewed below. 
 
In rat adrenal pheochromocytoma (PC12) cells and superior cervical ganglion (SCG) 
neurons, nerve growth factor (NGF) deprivation leads to a rapid increase in MLK3 
activity and apoptosis that can be reversed when MLK3 is blocked by overexpression 
of MLK3 kinase dead [46]. When cortical neuronal cultures are treated with amyloid-β 
peptide (Aβ), apoptotic cell death increases and a concomitantly increase in MLK3, 
MKK7, and JNK3 phosphorylation is also observed [47]. K252a, a potent inhibitor of 
MLK3, is able to decrease Aβ-induced cortical neuron apoptosis when added either 
before or after Aβ treatment. MLK3 was also found to be involved in the 
neuroprotective mechanism of exogenous estrogen against transient global cerebral 
ischemia, through inhibition of MLK3-MKK4/7-JNK1/2 pathway by Akt1 [48]. 
 
The role of MLK3 in modulating apoptosis events is also corroborated by other 
evidences. For instance, MLK3 directly phosphorylates golgin-160, a Golgi-associated 
protein, and its overexpression enhances the susceptiblility of golgin-160 to caspase 
dependent-cleavage [49]. The cleavage of several Golgi-proteins contributes to 
breakdown of the Golgi apparatus, which is an early event during apoptosis [50].  
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MLK3 activity is not exclusively related to its kinase activity as we already realized by 
its scaffold function in B-Raf-Raf-1 complex. MLK3 is also able to regulate JNK 
pathway, through its scaffold properties. It binds to a pro-apoptotic scaffolding protein 
with plenty of SH3s (POSH) that facilitates JNK signalling. The complex POSH-MLK-
MKK-JNK is negatively regulated by Akt2, that phosphorylates and inhibits MLK3, 
leading to complex disassembly and subsequent down-regulation of JNK pathway. 
Thus, POSH-MLK3 interaction increases when PI3K/Akt pathway is inhibited [51].  
 
From all these studies a model for the apoptotic and survival signalling pathways, 
through modulation of MLK3 activity by PI3K/Akt pathway was created (Figure 7). 
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Figure 7 - A model for the apoptotic and survival signalling pathways, mediated by MLK3 
phosphorylation. The inhibition of PI3K/Akt pathway by NGF deprivation leads to activation of 
GSK-3β, which in turn phosphorylates its downstream substrate, MLK3 on Ser
789
 and Ser
793
, 
leading to MLK3 activation and consequently to JNK-mediated apoptosis. On the other way, 
survival agents such as insulin and insulin-like growth factor 1 lead to the opposite effect by 
activating PI3K-Akt pathway. It causes GSK-3β phosphorylation at Ser
9
 and MLK3 
phosphorylation at Ser 
674
, leading to MLK3 inactivity and consequent cell survival, through JNK 
activity attenuation [25]. 
MLK3 may also mediate cell survival, through NF-kB pathway activation. Upon T-cell 
co-stimulation, MLK3 phosphorylates and thus activates both IĸB kinase alpha (IKKα) 
and IKKβ, which are the two catalytic subunits of the multisubunit IĸB kinase complex 
(IKC) capable of phosphorylating IkB proteins. Therefore IkB proteins are degraded, 
allowing the migration of NF-kB dimmers to the nucleus and consequently activation of 
NF-kB-dependent transcription [52]. Curiously MLK3-induced NF-kB activation is 
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dependent on the type of stimulus, seeing that upon TNF-α or interleukin-1 (IL-1) T 
cells stimulation MLK3 does not play an important role in NF-kB activation [52]. NF-kB 
activation seems to have an important role in cells survival, for instance it is associated 
to the response of tumour cells to hypoxic stress [53]. Therapeutic approaches implying 
IKK inhibitors as an adjuvant therapy have been suggested to overcome tumours cells 
resistance [54]. However other paper shows that inhibition of MLK3 expression leads to 
an increase of IKK activity levels, a decrease of IĸBα protein levels and to NF-kB 
dependent gene expression in both mouse embryo fibroblast cells (NIH3T3) and 
ovarian carcinoma cells (SKOV39) cells. Thus, in these cells MLK3 may confer 
resistance to ectoposide-induced apoptotic cell death [55]. On the other way, 
overexpression of wild-type MLK3 or MLK3 kinase dead enhanced etoposide-induced 
apoptotic cell death and cleavage of PARP, an enzyme involved in DNA repair. Maybe 
the cell lines studied and the kind of stimulus used in each experimental work may 
account for the variations in the results and for the role of MLK3 in NF-kB pathway 
activation. 
1.1.3.3 Role of MLK3 in intracellular trafficking and cell migration 
1.1.3.3.1 MLK3 scaffold properties in intracellular trafficking 
Again MLK3 kinase-independent activity may confer MLK3 involvement in different 
physiological functions. JNK-interacting proteins (JIP) proteins are other important 
scaffold proteins for JNK and p38 pathways. MLK3 interacts only with three members 
of this family: JIP1-3, which are widely expressed in nervous system [56-59]. JIP1 and 
JIP3 act exclusively to facilitate JNK pathway signalling, while JIP2 is both a p38 and 
JNK scaffold protein. Curiously, JIP1 and JIP2 interact, trough its COOH terminal with 
the proline-rich region of MLK3, while JIP3 binds selectively to MLK3, through its NH2 
terminal, and not to any other member of MAP3K [57-59]. 
 
Also interesting is that JIP1 and JIP2 exist in peripheral cytoplasmic projections, 
indicating a possible association with cytoskeletal proteins [59]. Accordingly, JIPs were 
found to interact directly with kinesins, which are motor proteins that transport cargos 
along microtubules in a specific direction - anterograde transport and in an ATP-
dependent manner [60]. This model for the transport of cargo by kinesin I involving JIP 
and MLK3 was already described for the transport of Reelin (extracellular matrix 
protein involved in neuronal migration during brain development) receptor [60]. MLK3 
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also interacts with kinesin superfamily proteins (KIF): KIF3A, KI3B, KIF17 and KIFAP3 
[61]. KIF17 was indeed described to efficiently transport NMDA receptor 2B subunits 
along microtubules [62]. All these MLK3 interactions prove the interesting role of MLK3 
in cellular trafficking. 
1.1.3.3.2 MLK3 regulates Rho activation 
JNK-deficients mouse and Drosophila melanogaster show defects in dorsal epidermis 
due to neural tube closure defects and to dorsal closure defects, respectively [63, 64]. 
Thus, JNK signalling, which is very conserved among vertebrates and Drosophila, has 
a critical role in epithelial cell migration that promotes dorsal closure [65]. Curiously  
MLK3-deficient mouse shows no developmental abnormalities, despite the reduction of 
the thickness of the dorsal epidermal tissue [30]. A homolog of mammalian MLK gene 
called slipper (slpr) was shown to be involved in dorsal closure in Drosophila [64]., 
Together these data suggest an interesting role for MLK3 in the migratory events 
induced by JNK signalling. 
 
Indeed MLK3 is required for cell migration but again in a kinase activity-independent 
manner. In MLK3-depleted cells the chemotactic index was very low compared with the 
control ones, but this level could be, at least, partially rescued by ectopic expression of 
nondepletable MLK3 [66]. The defects in cell migration were also translated into an 
increase in the thickness and number of stress fibers, as well as enlarged focal 
adhesions and absence of lamellipodial protrusions and were proved not to be related 
with inhibition of JNK, ERK or p38 phosphorylation. Interestingly, these MLK3-depleted 
cells presented high levels of activated Rho [66]. Increased activated Rho results in 
increased microtubule stability [67], a phenotype also observed following MLK3 
depletion [4]. 
The mechanism of MLK3-mediated Rho inhibition is downstream of active Gαq. The 
authors found that MLK3 interacts with the p63 Rho guanosine nucleotide exchange 
factor, p63RhoGEF, through its kinase domain and that this interaction is positively 
modulated after acute activation of a Gαq-coupled G protein-coupled receptor (GPCR). 
When MLK3 binds p63RhoGEF, it compromises the interaction of Gαq with p63Rho-
GEF, which is required for p63Rho-GEF activation and consequently for full activation 
of Rho downstream of Gαq (Figure 8). MLK3 phosphorylation on Thr277/ Ser281 
(residues localized within MLK3 kinase domain) and also Rac binding promote MLK3 
interaction with p63RhoGEF, while MLK3 phosphorylation by JNK decreases binding to 
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p63RhoGEF [66]. Thus, MLK3 seems to have a crucial role in regulation of Rho-
mediated migratory events. 
 
Figure 8 - Inhibition of Gαq-mediated Rho activation, by MLK3 binding to p63RhoGEF 
[66]. 
1.1.4 MLK3 related cancer 
In this chapter we will describe some of the few evidences in the literature that point 
MLK3 as being involved in tumour development and progression or as an interesting 
target for cancer therapy. Most of the data is still very inconsistent and controversial. 
The first evidence that MLK3 induces transformation was presented by Hartkamp and 
colleagues. In this report, overexpression of MLK3 results in the transformation of 
NIH3T3 fibroblasts and anchorage-independent growth, an ability that transformed 
cells acquired in vitro and is correlated with the potential of tumour cells to survive far 
away from each other without depending on interactions with extracellular matrix (a 
phenotype that is crucial to induce metastasis) [36]. However, in another study with 
NIH3T3 cells that co-expressed wild-type MLK3 and a Rac mutant, the MLK3 kinase 
activity was reported to inhibit Rac1 transforming activity and wild-type MLK3 alone had 
not the ability to transform these cells [68]. The inconsistency between results can be 
due to the different MLK3 constructs used or to the different susceptibilities of NIH3T3 
strains to transformation [68]. 
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1.1.4.1 MLK3 in tumour cell proliferation.  
It was demonstrated that MLK3 is not only required for normal cell proliferation but also 
for tumour cell proliferation. MLK3 silencing, through RNAi, was shown to prevent 
proliferation of tumour cells harbouring either oncogenic K-Ras or loss-of-function NF1 
or NF2 mutations [37]. NF2 gene encondes merlin, a protein that binds MLK3 and 
consequently disrupts the interaction between the members of B-Raf-Raf-1-MLK3 
complex. On the other hand, MLK3 silencing in tumours cells bearing either B-Raf or 
Raf-1 mutations did not affect proliferation [37], demonstrating that MLK3 is an 
upstream molecule of B-Raf and Raf-1 
 
Curiously the MLKs inhibitor CEP-11004, which was proved to target MLK3 more 
specifically than other isoforms of MLK family, was able to inhibit mitotic transitions and 
cell proliferation in transformed cells, such as human epithelial cervical cancer HeLa 
cells, human lung adenocarcinoma epithelial cells (A549), ER negative SUM159 breast 
cancer cells or human embryonic kidney 293 (HEK293) cells but not in non-
transformed NIH 3T3 or normal diploid human MRC-5 lung fibroblasts [69]. The effect 
of this inhibitor on mitotic arrest in pro-metaphase could be explained by the observed 
defects in microtubule organization and aberrant spindle formation induced by the 
inhibitor. At least in HeLa cells the arrest in pro-metaphase was partially reversed by 
overexpressing MLK3. Knowing that MLK3 is related to NIMA, which phosphorylates 
histone H3 Ser10 in vitro, it is interesting to observe a delay of histone H3 
phosphorylation in early mitosis, upon treatment with CEP-11004 [4, 69, 70]. Because 
MLK3 is thought to be a more specific target of CEP-11004 than others MLKs, it was 
suggested a direct or indirect involvement of MLK3 in the reported events. 
 
Maybe pharmacological inhibition of MLKs, namely MLK3, could be a good therapeutic 
approach to prevent cancer cell proliferation in at least cases without alterations of B-
Raf or Raf-1. 
1.1.4.2 MLK3 overexpression in tumours 
Our group has recently investigated the levels of MLK3 expression in human breast 
and gastric cancer cell lines, by real-time polymerase chain reaction (Real-time PCR) 
and found that a large number of breast and gastric cancer cell lines show a higher 
level of MLK3 expression when compared to the normal breast and normal stomach, 
respectively (data not published and related results will be discussed later in this 
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thesis). But this increased level of MLK3 in tumours was also described in other models 
like in pancreas. 
 
Pancreactic cancer cells. MLK3 protein levels were found to be three-fold higher in 
pancreatic cancer cell lines, when compared to an immortalized pancreatic epithelial 
cell line. The inhibition of MLK3 expression in pancreatic cancer cell lines either 
through siRNA or by using K252a lead, in both cases, to a reduction of cell proliferation 
and a decreased activation of ERK, JNK and Akt. Taking into account that most of 
pancreatic cancers harbour oncogenic K-Ras [71] mutations and knowing that in those 
cases MLK3 inhibition prevents cell proliferation [37] it makes sense that inhibition of 
MLK3 alone blocks pancreatic cell proliferation. However, pancreatic cancer cell lines 
also overexpress epidermal growth factor (EGF) receptors (EGFR), so coupling EGFR 
inhibition to MLK3 inhibition may cause a dramatic decrease in phosphorylation of Akt, 
an increased cleavage of PARP and an increase in cleaved caspase-3 activity that is 
not verified in MLK3 inhibition alone. In fact, the inhibition of both MLK3 and EGFR lead 
to apoptosis of pancreatic cancer cells [72]. New clinical trials are evaluating the 
presumable more effective action of combined therapies against advanced pancreatic 
cancer [73]. Maybe the use of both EGFR and MLK3 inhibitors would lead to pancreatic 
cancer cells death and could herein be a good combined therapeutic approach. 
 
Head and neck squamous cancer (HNSCC) cells. Curiously MLK3 is also 
overexpressed in malignant HNSCC cell lines, compared to normal tonsil lysate [74]. 
MLK3 was inhibited, as described for pancreatic cancer cells, and the results were very 
similar. It was observed a downregulation of phospho-Akt and phospho-ERK and a 
decrease in cell proliferation. As HNSCC cells also overexpress EGFR, the same 
therapeutic approach as used above was performed: MLK3 inhibition coupled to EGFR 
inhibition. This combination induced less phospho-Akt expression and increased 
apoptosis (caspase 3 or PARP cleavage) compared with EGFR inhibition alone. From 
these results we may say that MLK3 has probably a role in avoiding apoptosis in 
HNSCC cells. 
 
Thus, MLK3 inhibition may enhance the effects of EGFR inhibition either in pancreatic 
cancer cells or in HNSCC cells. 
 
Breast cancer cells. According to our group results, breast cancer cell lines present 
high levels of MLK3 protein, comparing to non-tumorigenic ones, what was also verified 
by Chen and colleagues [75]. MLK3-induced expression leads to an increase of 
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migration either of the poorly invasive MCF7 breast cancer cells or of MCF10A 
mammary non-tumourigenic epithelial cells. This effect was accompanied by JNK and 
p38 activation, but not ERK one, despite basal ERK activation being necessary to 
migration [75]. Curiously, MLK3 gene was also identified as a modulator of migration, 
among over 60 genes, in a wound healing screen, using a siRNA approach, with 
MCF10A cells [76]. MCF10A cells overexpressing wild-type MLK3 were three-fold more 
invasive than those expressing the control vector. Activation of JNK pathway, trough c-
Jun phosphorylation and activation of AP-1 transcription factor seems to be crucial to 
the acquisition of this aggressive and consequently malignant phenotype. Thus MLK3-
JNK-AP-1 signalling seems to develop a crucial role in carcinogenesis of breast cells 
[75]. 
 
In gastric cancer cells this effect of MLK3 in cell migration was determined. Over 
the past two decades it has been established a link between high expression levels of 
gastrin, which is a gastrointestinal peptide hormone produced by the gastric G cells 
and gastrointestinal cancer (reviewed in [77]). Amidated gastrin (G17), the fully 
processed amidated form of gastrin, was demonstrated to induce gastric cancer cells 
migration [78]. This effect was preceded by an activation of ERK, JNK and p38. 
Besides the well-known JNK1 role in apoptosis its activation was already shown to be 
crucial for both tumour initiation and promotion in gastric cancer [79]. In agreement, 
inhibition of JNK was shown to be more critical to G17-induced migration than the 
inhibition of the other MAPKs. Not only JNK1 but also MLK3, which activity is induced 
up to 1h after G17 addition, seem to be involved in this migratory process. JNK 
downstream mediators of migration are not well known, but this study point c-Jun as 
one of them. The activation of MLK3/JNK/c-Jun induced by G17 also leads to an 
increase of the metalloproteinase 7 (MMP7) promoter activity. Increased expression of 
MMP7 was found to stimulate gastric epithelial cell migration in a subset of gastric 
epithelial cells infected with the gastric oncogenic pathogen Helicobacter pylori [80]. 
MMP7 transcriptional activation was abolished after knocking down of MLK3 
expression [78]. Together these data seem to pinpoint a role for MLK3 in mediating 
G17-induced migration in gastric cancer cells, through JNK activation.  
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1.1.4.3 Promoting MLK3 activation in tumours 
Surprisingly, the promotion of MLK3 activity could also be an adjuvant strategy to treat 
tumours. 
 
Breast cancer cells. MLK3 kinase activity was found to be about five-fold higher in 
breast tumours with both estrogen and progesterone receptor-negative (ER-, PR-), than 
in ER+, PR+ ones. Such data suggests that estrogen might be negatively interfering with 
MLK3 activity [81]. Thus, 17β-estradiol (E2), which is the predominant estrogen form 
that binds strongly to ERα, was proved to be negatively regulating MLK3 kinase activity 
as well as its downstream activation of JNK, but only in ER+ breast cancer cells. This 
inhibition is ER-dependent and occurs via PI3K/Akt pathway, being Akt the kinase 
responsible for MLK3 phosphorylation at Ser674. This phosphorylation reduces MLK3 
proapoptotic activity, through attenuation of JNK activity. So, in ER+ tumours, E2 
promotes cell survival and proliferation probably by downregulating the proapoptotic 
activity of MLK3 [81]. Therefore antiestrogen treatment of breast cancer cells remains a 
mainstay of therapy for tumours expressing ERα [82] and agents that can activate 
MLK3 and at the same time block Akt phosphorylation might also have a beneficial 
effect.  
 
Prostate cancer cells. In patients with prostate cancer in the early, androgen-
responsive stages of the tumour, androgen ablation and consequent administration of 
gonadotropin releasing hormone analogs (GnRH-a) is the standard therapeutic 
approach, due to GnRH-a antiproliferative effect [83]. However, in hormone-refractory 
prostate cancer cell lines, GnRH-a was also able to induce apoptosis. GnRH-a-induced 
apoptosis leads to JNK and ERK1/2 activation and to Akt dephosphorylation. It was 
also confirmed a significantly reduction of MLK3 phosphorylation on the Akt 
phosphorylation site. The authors suggest that MLK3 may mediate this increase in JNK 
activity after the reduction of MLK3 phosphorylation on its inhibitory site, by Akt [84].  
 
Genipin is a natural compound that has been implicated in apoptosis of hepatoma 
cells. Its action is mediated via NADPH oxidase-dependent generation of reactive 
oxygen species (ROS), which leads to downstream activation of JNK [85]. MLK3 was 
also found to be a link between ROS signalling and JNK activation in genipin-induced 
apoptosis in PC3 human prostate cancer cells. It appears that genipin induces ROS 
formation, which then induces MLK3 phosphorylation and activation and finally leads to 
cells apoptosis, through downstream activation of JNK. When ROS generation is 
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inhibited in the genipin-treated cells MLK3 phosphorylation was blocked. MLK3 activity 
was proved to be important for genipin-induced apoptosis as cells expressing a 
dominant-negative MLK3 mutant (K144R) were less susceptible to this effect. This was 
demonstrated by an impairment of cytocrome c content, no changes in mitochondrial 
membrane potential and less stimulation of caspase-3 activity. So, MLK3 seems to be 
an important mediator of genipin-induced apoptosis PC3 cells [86]. 
1.1.4.4 MLK3 may potentiate taxol antitumour activity 
Paclitaxel (taxol) acts as an anti-cancer drug in many tumours, such as breast tumours 
[87]. Its effect was first attributed to microtubules stabilization, through direct binding to 
them, what consequently avoids mitosis and stops cell proliferation [88]. As already 
mentioned MLK3 seems to cause microtubules disruption when ectopically expressed 
and if its depletion increases cellular sensitivity to taxol at low concentrations it 
suggests that MLK3 absence results in a partial stabilization of the microtubule network 
and as it is non toxic to cells MLK3 depletion/targeting could be an interesting adjuvant 
therapy to taxol treatment [4]. 
 
On the other hand, taxol also activates the JNK signalling, inducing cell death [89]. 
However when ER+ cells were first stimulated with E2 and then with taxol, cell death 
was reduced [81]. This happens due to the probably MLK3 down-regulation induce by 
E2. In this case MLK3 depletion would not probably be a good option. In particular, in 
the case of estrogen-dependent breast cancer tumours agents that could active MLK3 
and inhibit Akt simultaneously might have clinical relevance [81].  
 
Together all data indicate that, depending on the cellular context, MLK3 depletion or its 
increased activation could increase cells sensitivity to taxol, thus becoming the 
treatment more effective. However, before defining the best therapeutic strategy it is 
crucial to determine the role of MLK3 in each specific situation, as MLK3 induces 
different cellular effects according to the cell line and tumour model. 
1.1.4.5 MLK3 mutations in tumours 
The investigation that our group was taking on about gene expression of MLK3 in 
human cancer cell lines was extended to the identification of MLK3 mutations in 
colorectal cancer lines. As verified for gastric and breast cancer cell lines, also 
colorectal cancer cell lines present high levels of MLK3 expression. However, some 
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colorectal cancer cell lines show similar levels of MLK3 expression when compared to 
normal tissue. This is the case for two colorectal carcinoma cell lines (RKO and 
CO115). As widely known, mutations in many genes may strongly alter signalling 
pathways and by this way interfere with different physiological functions such as 
proliferation or apoptosis, two important processes in a carcinogenic process. For 
instance B-Raf mutations are known to be prevalent in many human cancers such as 
colorectal cancer (5%-22%) and most of these mutated genes are translated into 
mutant B-Raf proteins that present high levels of kinase activity, which stimulate ERK 
signalling in cells (reviewed in [90]). In the same way it is well possible that also MLK3 
mutations are an alternative mechanism to maintain cell survival in tumours or induce 
other functional effects pivotal for tumour progression, namely migration. 
 
In fact in 2010 our group described for the first time MLK3 gene structural mutations in 
cancer [11]. In the case of gastrointestinal cancer MLK3 mutations were related to the 
microsatellite instability (MSI) phenotype. Mutations were also found in colorectal 
cancers cell lines with MSI (RKO and CO115), mimicking what was observed for 
primary tumours. Curiously, in half of the MSI primary gastrointestinal tumours tested, 
MLK3 mutations were found together with wild-type B-Raf and K-Ras genes. In the 
series of cases studied, somatic missense mutations were more prevalent than 
frameshift ones. Most of them occurred in functional domains of the protein and affect 
amino acids that are evolutionary conserved (Figure 9). To better understand the 
potential impact of some of these mutations, 3D protein predictive studies were 
performed using the crystal structure of the kinase domain of MLK1 as a model. They 
all seem to interfere with scaffold properties of MLK3, rather than with its kinase 
activity. After, the transforming potential of mutations localized in different domains was 
tested either in vitro or in vivo. P252H and R799C mutations had the highest fold (4x) 
increase in focus assay, compared to Mock, despite all the mutations analysed 
presented significant transforming potential in vitro. P252H mutation is localized in 
MLK3 kinase domain, while R799C localizes in the P/S/T-rich domain. These two 
mutations were inoculated in nude mice and tumours were developed within five 
weeks, while Mock and wild-type MLK3 expressing cells were not able to generate 
tumours not even after six weeks. The tumours were analysed and a high number of 
mitotic figures and an infiltrative pattern of growth was observed for tumours 
expressing MLK3 mutant cells. The ability to invade was also proved in vitro in a 
matrigel assay. So, this paper reveals an important role for cancer-related MLK3 
mutations, but more studies are required to understand the signalling pathways 
associated to them. 
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Figure 9 - Summary of the localization of missense mutations in MLK3 gene found in MSI 
primary carcinomas and cell lines and the mutated aminoacid residues they originated. 
The evolutionary conservation of the correspondent wild-type amino acid residues was studied 
within mammalian orthologues and within eukaryotic homologues [11] 
Later on to understand the role of P252H mutation, which seems to have the most 
aggressive phenotype either in vitro or in vivo, the same authors performed a 
microarray expression profiling of biological triplicates of HEK293 cells transfected with 
mutant, wild-type and empty vector (Mock) (data not published). The expression 
profiles allowed the identification of genes at least 2 log-fold differentially expressed 
between wild-type and Mock, as well as between P252H and Mock. It was found a 
significant differential expression between P252H and wild-type in 445 genes. 
Curiously, the colorectal pathway, which encompasses several relevant pathways such 
as WNT, MAPK, NOTCH, transforming growth factor-beta (TGF-β) and P53, was 
significantly over-represented, what corroborates with the discovery of P252H mutation 
in a colorectal tumour. Together these data suggest that mutant MLK3 deregulates 
important pathways involved in colorectum differentiation.  
 
The expression of some of those genes was confirmed by Real-time PCR. Cyclin D1 
(CCND1), lymphoid enhancer-binding factor-1 (LEF1) and bone-morphogenetic protein 
6 (BMP6) genes were confirmed to be down-regulated, while frizzled homologue 10 
(FZD10) was confirmed to be up-regulated in P252H, always comparing with wild-type 
MLK3 expressing cells. CCND1 and LEF1 are associated to the activation of the 
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canonical WNT pathway, while FZD10 is involved in the non-canonical one [91]. This 
was the first time that MLK3 is reported to be related to WNT pathway. 
 
 
 
 
So regarding all data about MLK3 role in tumours we may suggest MLK3 as novel 
oncogene, often mutated in mismatch repair deficient tumours, where it confers 
transforming and invasive potential by deregulating several fundamental colorectal 
cancer-related pathways. From now on it is important to understand, not only the 
signalling pathways associated to MLK3 mutations, but also the cellular effects induced 
by them. 
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Chapter 2       Project aims 
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The purpose of this thesis is included in the objectives of the FCT project entitled 
“MLK3, a new mutated gene in MSI colorectal cancer”, that is being developed in our 
laboratory. This project is related to the tumorigenic role of MAPkinases in MSI cancer, 
namely the role of MLK3. As already mentioned MLK3 mutations were described for 
the first time by Raquel Seruca´s group. However, we urge to understand the 
importance of these mutations in cancer development and progression. In order to 
achieve that it was important to evaluate the cellular effects and activated signalling 
pathways mediated by those mutations. So, this experimental work intends to be a 
scientific approach to better understand the role of MLK3 in cancer. For that, different 
aims were proposed. 
 
1) To evaluate the cellular effects associated to P252H mutation and which signalling 
pathways could it be interfering with.  
 
3) To understand if the observed effects were independent or not on the localization of 
the mutation in the different MLK3 domains. In order to verify the putative genotype-
phenotype correlations we studied another MLK3 mutations localized in a distinct 
domain of the protein – R799C. 
 
4) Finally we want to verify if wild-type MLK3 overexpression leads, in similar or distinct 
manner, to the effects and signalling alterations verified for the previous MLK3 
mutations. 
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2 Chapter 3      Material and Methods 
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The Figure 10 represents an overall view of the different assays performed, as well as 
cell lines used in each one, during this work to better understand and correlate all data. 
 
Transient expression
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Figure 10 - Schematic representation of this experimental work. 
2.1 Cell culture 
In this experimental work four epithelial cell lines from human origin: RKO, HEK293, 
BT20 and MCF7, and one epithelial-like of hamster origin – CHO were used. All of 
them were cultured in Dulbecco’s modified Eagle’s medium - DMEM (High Glucose) 
(Gibco, Invitrogen) or in Minimum Essential Medium Eagle with Alpha Modification – α-
MEM (Gibco, Invitrogen). The supplements used depended on the specificities of each 
cell line: fetal bovine serum – FBS (HyClone, Perbio), penicillin–streptomycin - PS 
(Gibco, Invitrogen), sodium bicarbonate 7,5% (Gibco, Invitrogen), sodium pyruvate 
MEM 100mM (Gibco, Invitrogen) and blasticidin (Gibco, Invitrogen). These and other 
details are described inTable I. 
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Table I - Detailed information of the cell lines used in this experimental work. 
Some data was provided by ATCC, http://www.lgcstandards-atcc.org/. 
Designation Source Culture medium – Observations 
RKO
1
 
 
colon (carcinoma) 
DMEM supplemented with 
10%FBS , 1% PS, 1mM 
sodium pyruvate, 150mg/mL 
sodium bicarbonate 
Biosafety Level:1 
Cell line with multiple genetic 
alterations (ex: B-Raf and MLK3 
mutations) 
HEK293 
 
embryonic kidney 
• parental cell line 
DMEM supplemented with 
10%FBS , 1% PS 
• stable cell lines 
DMEM supplemented with 
10%FBS , 1% PS, blasticidin 
(8µg/mL) 
Biosafety Level:2 [cells contain 
adenovirus ] 
CHO 
 
ovary α-MEM (Gibco) Biosafety Level:1 
MCF7 
 
breast 
(adenocarcinoma 
from metastatic site) 
DMEM supplemented with 
10%FBS , 1% PS 
Biosafety Level:1 
 
Cells were grown at 37˚C in a humidified atmosphere of 5% CO2. When cells needed to 
be divided, they were washed in physiological serum and incubated with trypsin-EDTA 
(Gibco, Invitrogen) to detach them and then were resuspended in medium. Before 
freezing cells, they were first trypsinized and centrifuged at 1200rpm for 5 minutes, 
then they were resuspended in FBS with 10% DMSO (Sigma) and finally the content 
was divided by cryovials (CRYOVIAL®) and kept at -80ºC in a cryogenic freezing 
container (Nalgene) that contains 100% isopropanol (Merck). This box system allows a 
slow cooling rate of -1° per minute. 
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2.2 Establishment of HEK293 stable cell lines 
The Figure 11 represents an overview of all procedures we performed to obtain 
HEK293 stable cell lines. 
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Figure 11 - Schematic representation of the establishment of HEK293 stable cell lines. 
(Steps before HEK293 transfection, indicated in the figure as an asterisk (*), were previously 
performed by our group. [11]. First, wild-type and mutants sequences were generated by site-
directed mutagenesis, cloned into pLENTID6/V5 vector and the empty vector (Mock) was 
obtained by the insertion of a small fragment of cDNA. After, Escherichia coli cells were 
transformed with the constructs generated, colonies were then selected, plasmids were purified 
and the sequence cloned was confirmed by direct sequencing. If the sequence was correctly 
inserted, then glycerol stocks with the selected clones were prepared.) Finally, the different 
vectors were inserted in HEK293 cell line and transfected cells were selected with blasticidin. 
MLK3 sequence and MLK3 levels were analysed, before performing functional assays and 
testing expression levels of target proteins, to guarantee that everything was according to what 
was expected. 
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2.2.1 Maxiprep preparation 
A maxiprep was prepared using Plasmid Maxi Kit (QIAGEN) to increase the amount of 
the empty vector. The protocol used was based on manufacturer´s instructions but with 
some alterations. Seventy µL of the glycerol stock, which is composed of a culture of 
Escherichia coli that harbours the empty vector, was grown into 300mL of Lysogeny 
Broth/ Ampicilin medium at 37ºC overnight. The material was then separated in six 
Falcons of 50mL and centrifuged at 4000g for 20 minutes at 4ºC. The supernatant was 
poured off and Buffers P1, P2 and P3 were added. Other centrifugations at 14000g for 
40 minutes and at 14000g for 20 minutes, both at 4ºC, were performed. After 
equilibrating and washing the QIAGEN column, the DNA was eluted by adding 15mL of 
Buffer QF, precipitated with isopropanol and centrifuged at 9000g for 50 minutes at 
4ºC. After washing DNA pellet with etanol 70% it was centrifugued at 9000g for 30 
minutes. DNA pellet was air-dried and resuspended in water. Its concentration was 
measured at 260nm. 
2.2.2 Transfection 
HEK293 cell line was transfected with empty vector (Mock) and wild-type MLK3 and 
mutant (P252H and R799C) sequences in triplicate, using Lipofectamine™ 2000 
Transfection Reagent (Invitrogen) according to manufacturer´s instructions. 
Transfected cells were selected through its resistance to 8µg/mL of blasticidin 
(Invitrogen) and a group of resistant clones was mixed together. In the end of all 
process three replicas per each vector sequence were obtained and termed T1, T2 and 
T3, except for empty vector that had only one replica. HEK293 MLK3 R799C and 
HEK293 wild-type MLK3 stable cell lines were previously prepared in our laboratory.  
2.2.3 RT-PCR 
RNA extraction. RNA extraction was performed with TriPure Isolation Reagent 
(Roche) according to the instruction manual. RNA was quantified with NanoDrop ND-
1000 (Alfagene) and water with DEPC, in which RNA was diluted after extraction 
procedure, was used as a negative control. 
Priming. First, 2µg of RNA, 0,1ng of Random Primers 100ng/µL (Invitrogen) and water 
with DEPC (inhibitor of ribonucleases), in a final volume of 12µL, were put together in a 
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microcentrifuge tube that was incubated at 70ºC for 10 minutes. After that, samples 
had to be kept on ice for 2 minutes. 
cDNA production. The following mix was prepared and added to the previous one: 1x 
first strand buffer (Invitrogen), 10mM DTT 0,1M (Invitrogen), 0,5mM dNTPs 10mM 
(Bioron), 8U of rRNasin® (Promega), 150U of SuperScript™ II Reverse Transcriptase 
(Invitrogen) and water with DEPC. A final volume of 20µL was incubated at 37ºC during 
1 hour, in the termocyler. 
2.2.4 PCR for MLK3 amplification  
DNA extraction. DNA extraction was performed with Spin Tissue Mini Kit (Invisorb) 
according to the instruction manual. DNA was quantified with NanoDrop ND-1000 
(Alfagene) and the elution buffer D from the DNA extraction kit mentioned above was 
used as a negative control. 
PCR. In a microcentrifuge tube was prepared a mix with the following components: 1x 
PCR Amp Buffer (Invitrogen), 0,8mM dNTP 10mM (Bioron), 0,4µM of each forward and 
reverse primers 10µM (Sigma) (Table II), 1U of Taq DNA Polymerase (GE Healthcare), 
DNA or cDNA and water, in a final volume of 25µL. The PCR-reaction occurred then in 
a thermocycler beginning with the denaturation of DNA or cDNA molecule at 95ºC for 5 
minutes, followed by 35 cycles of the combination of a denaturation step - 95ºC for 30 
seconds -, an annealing step - 60ºC for 45 seconds - and an extension step - 72ºC for 
1minute -, finishing with a final elongation step at 72ºC for 10 minutes and a final hold 
of 15ºC.  
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Table II - Primers used in amplification of MLK3 gene. Abbreviation: Tm, 
melting temperature 
Primer name Sequence 5’-3’  Tm PCR-fragment size (KDa) 
MLK3_Ex1F1 GCTTTGGCAAGGTGTACAGG 62 
MLK3_Clon1R ATGTGCTGGTCAACTGGGCT 67,0 
278 
CMV Fw CGCAAATGGGCGGTAGGCGTG  
MLK3_Ex1R CAGCTGCCCCTGTACACCTT 64 
503 
MLK3_Clon1F ATGGAGCCCTTGAAGAGCCTC 75,1 
MLK3_Clon1R ATGTGCTGGTCAACTGGGCT 67,0 
657 
MLK3_Clon1F CACC CACCATGGAGCCCTTGAAGAGCCTC  
MLK3_Clon1R ATGTGCTGGTCAACTGGGCT 67,0 
661 
MLK3_Clon2F CTGTGCCTGGTGATGGAGTATG 66,6 
MLK3_Clon2R CTCACACTGCCCATCCCATC 67,9 
470 
MLK3_Clon3F GCAGTGACGTCTGGAGTTTTG 64,8 
MLK3_Clon3R AGTGGGAGCTAGAGGTGTTCGA 66,2 
457 
MLK3_Clon4F CGAGCCAAGGAAAAGGAACTAC 64,8 
MLK3_Clon4R ACTCAAGCAATGGAGAGCGG 66,6 
450 
MLK3_Clon5F ACGTCTGGAGGACTCAAGCAA 66,1 
MLK3_Clon5R GGGTGCCGGAAGCGGGGCCT 80,5 
892 
MLK3_Clon5F ACGTCTGGAGGACTCAAGCAA 66,1 
MLK3_2725 _Rv GACATCACGCTCTGCTCCTG 66,3 
602 
MLK3_2725_ Fw GACATCACGCTCTGCTCCTG 66,3 
p_LENTI_V5b = CGGGCCCTCTAGACTCGA 65,5 
 
2.2.5 Agarose gel electrophoresis 
The result of the PCR reaction was visualized in a 2% agarose gel. To prepare the gel, 
SeaKem® LE Agarose (Lonza) was dissolved in 1x Tris-borate-EDTA (TBE) buffer and 
1,5µL/50mL of the GelRed™ Nucleic Acid Gel Prestaining Kit with “50bp” Tracking Dye 
were added before solidification of the gel. After it, a volume of 28µL per sample 
(already containing bromophenol blue) and 5µL of the 1Kb Plus DNA Ladder 
(Invitrogen) were loaded and the gel ran at 120V. An image of the gel was captured 
with the Molecular Imager® Gel Doc™ XR+ system (BioRad). As the final purpose of 
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these agarose gels was to purify the PCR products, the bands were cut with a surgical 
blade (Sofdan) in the ultraviolet (UV)  transiluminator and then kept in eppendorfs at 
4ºC until use.  
2.2.6 Sequencing 
Agarose bands purification. PCR product from the cut bands was purified with illustra 
GFX PCR DNA and Gel Band Purification Kit (GE Heathcare), according to the 
manufacturer´s protocol. 
Sequencing reaction. Two mixs were prepared: one with the forward primer and the 
other with the reverse one (the primers used were those mentioned above to amplify 
MLK3 fragments). The common components of each mix were: 0,8µL of Big Dye 
Terminator v3.1, 1,67x of Big Dye Terminator sequencing buffer (Applied Biosystems), 
1µM of forward or reverse primers 10µM (Sigma), purified cDNA or DNA and water. 
After preparing two mixs per each DNA or cDNA, samples were incubated in the 
thermocycler at 96ºC for 2 minutes (denaturating step), followed by 25 cycles of three 
steps (96ºC for 30 seconds, 54ºC for 15 seconds and 60ºC for 3 minutes), finishing 
with a step of 60ºC for 10 minutes and a final hold at 10ºC. 
Reaction Purification with Sephadex. Sephadex is a gel composed of macroscopic 
beads that allows the purification of DNA/cDNA after labelling reactions, i.e. removal of 
un-incorporated dyes or dye terminators. As it is supplied as a dry powder, it must be 
allowed to swell in water before use (6,6g/100mL). To initiate purification first the 
columns were washed at least twice: a GFX Microspin Column (GE Healthcare) was 
placed into one Collection tube, and water was added to the top and it was centrifuged 
at 14000rpm for 10 minutes. After that the Sephadex G-50 Fine (GE Healthcare) was 
added to the Microspin columns and centrifuged at 4400rpm for 4 minutes, resulting in 
the formation of a porous column. Then, the collection tube was changed by an 
eppendorf and finally the sample was added to the center of the sephadex column and 
centrifuged at 4400rpm for 4min, which allowed the elution of the purified product into 
the collection tube. After adding 12µL of Hi-Di™ Formamide (Applied Byosystems), 
which denatures the DNA/cDNA template from the newly synthesized strands, 
increases sample preservation and dissolves local secondary structures, the samples 
were ready to be sequenced. 
Detection on an automated sequencer. Samples reading was done with the Genetic 
Analyzer 3130 (Applied Biosystems) and data was edited with Sequencing Analysis 
v5.2 software (Applied Biosystems). 
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2.3 Transient transfections 
Cells were transiently transfected either with a siRNA targeting a mutation in MLK3 
sequence – P252H (QIAGEN) or siRNA targeting wild-type MLK3 (Dharmacon) (details 
in Table III). Cells were counted using a 0,0025 cm2 Neubauer chamber (Marienfeld) 
and plated in a 6-well plate. The transfections were performed in the next day using 
Lipofectamine™ 2000 Transfection Reagent (Invitrogen) (6µL/mL and 2,5µL/mL for 
RKO and HEK293 cell lines, respectively), according with the instructions manual. 
Three controls were used: blank (cells cultured without any reagents), siRNA control 
(cells cultured only with a non specific siRNA – AllStars negative control (QIAGEN)) 
and lipofectamine control (cells cultured only with the lipofectamine reagent). Opti-
MEM® I Reduced Serum Media (Gibco, Invitrogen) was used in the blank control and 
to dilute siRNA in the others samples. The medium was changed 4 to 6 hours after 
transfection and protein extraction or cellular assays were performed 48 hours after 
transfection. 
Table III – Details of the transfection with siRNA of RKO and HEK293 cell 
lines. 
[siRNA] (nM) 
Cell line 
Cells per 
well siRNA non- specific siRNA wild-type MLK3 siRNA MLK3 P252H  
RKO 1,7 x 10
5
 250 - 250 
HEK293 Mock 4 x 10
5
 150nM 50,100 and 150nM - 
2.4 Snapshot 
PCR to amplify GAPDH and MLK3 cDNA flanked P252H regions. Mixs for the 
housekeeping gene (GAPDH) and for the cDNA of interest (MLK3) had the following 
components in common in a final volume of 25µL: 1x of Buffer Taq (GE Healthcare), 
0,8mM of dNTPs 10mM (Bioron), 800nM of both forward and reverse primers for RKO 
or GAPDH 10µM (Sigma) (Figure 12), 0,5 U of Taq DNA polymerase (GE Healthcare), 
2µL of cDNA, and water. A mix for negative control was also prepared. The PCR 
programme used consisted of a first step at 95ºC for 5 minutes to denature the cDNA 
template; followed by a cycle repeated 35 times (95ºC for 30 seconds, 58ºC for 30 
seconds and 72ºC for 30 seconds), a final extension step at 72ºC for 7 minutes and a 
final hold of 15ºC.  
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PCR products purification. After amplification the products were loaded in an 
agarose gel, previously prepared, and were purified with Gel Band Purification Kit (GE 
Heathcare), according to the manufacturer´s protocol. 
Snapshot reaction Purified products from both GAPDH and MLK3 mixs were put 
together in equal volumes (1µL of each one). To 1µL of this mix were added 600nM of 
RKO Snapshot primer, 600nM of GAPDH Snapshot primer (Figure 12), 1µL of 
Snapshot mix (Applied Biosystems) and water. The PCR programme used consisted of 
a cycle repeated 25 times, divided in three steps: 95ºC for 15 seconds, 50ºC for 5 
seconds and 60ºC for 30 seconds and a final hold of 4ºC. 
Purification of Snapshot PCR products. 1µL of the previous mix was added to 1U 
FastAP™ Thermosensitive Alkaline Phosphatase (Fermentas). Then the following 
three-step PCR programme was performed: 37ºC for 15 minutes followed by 85ºC for 
15 minutes and a final hold at 4ºC. 
GenScan analysis. Finally, 0,5µL of 120 LIZ GeneScan size standard (Applied 
Biosystems) and 11µL of formamide (Applied Biosystems) were added to 0,5µL of the 
previous mix. The samples were then read in the ABI PRISM® 310 Genetic Analyzer 
(Applied Biosystems). 
Figure 12 - Primers sequences used in snapshot procedure. 
Primer Primer sequence 5´- 3´ PCR fragment size (bp) 
GAPDH Fw TCAAGGCTGAGAACGGGAAG 
GAPDH Rv CAGTAGAGGCAGGGATGATG 
456 
RKO Fw CCCTGGTGCC CGTCATCCA 
RKO Rv AAAACTCCAGACGTCACTGCC 
227 
GAPDH Snapshot GCGAGATCCCTCCAAAATCAA - 
RKO Snapshot TCCAACAACATTTTGCTGCTGCAGC - 
2.5 Western Blot 
Protein extraction. Cells from T-25 or 6-well plate were grown until subconfluence. To 
perform protein extraction cells were put on ice, the medium was removed and cells 
were washed twice with PBS1x. The cell lysis occurred when the lysis buffer was 
added to the cells monolayer. It was composed of RIPA buffer enriched with a protease 
inhibitor cocktail (Roche) and a phosphatase inhibitor cocktail (Sigma). The lysis 
 49 
content was removed with a cell scraper, collected, transferred to a tube and then 
centrifuged at 14000rpm for 10 minutes at 4ºC. The resulting supernatant, which 
corresponds to the total cell lysate, was kept at -20ºC. Protein quantification was 
performed in 96-well plate with detergent-compatible protein assay (BioRad) which is a 
colorimetric assay similar to Lowry assay. The assay was performed according to the 
manufacturer’s instructions. To construct the standard line bovine serum albumin 
(Sigma) standards were previously prepared with the following concentrations: 0,25 ; 
0,5 ; 0,75 ; 1; 1,5 and 3mg/mL. The absorbance was read on the spectrophotometer 
(BioRad) at 655nm. 
 
Sample preparation. After quantification, 25µg of protein were used to perform 
western blot. The correspondent volume was mixed with water and 4x Laemmli buffer 
and boiled at 95ºC for 5min.  
Electrophoresis. After mounting the Mini-PROTEAN 3 cell (BioRad) the separating gel 
monomer solution was poured between the glasses. After its polymerization, the 
resolving gel was plated above together with the comb. Samples and PageRuler™ 
Plus Prestained Protein Ladder (Fermentas) were loaded and the gel ran immersed in 
1x TGS Tris/Glycine/SDS buffer (BioRad) for about 1h30 at 120V and 400mA. 
Immunoblotting. The proteins were transferred from the gel to a nitrocellulose 
membrane (Amersham Hybond™ ECL™ (GE Healthcare)) with Mini Trans-Blot® 
Electrophoretic Transfer Cell (BioRad) during 1h30 at 100V and 400mA, according to 
the instruction manual. To confirm the transference efficiency, nitrocellulose membrane 
was stained with Ponceau S dye (Sigma) and bands were rapidly visualized. 
Membrane blocking and antibody incubations. The membranes were blocked in 5% 
powdered milk (Nestlé Molico) in PBS-Tween 0,5% during 1 hour at room temperature 
or at 4ºC during overnight. Then they were incubated with primary antibodies (listed on 
the Table IV) during overnight. Most of the antibodies were diluted in milk 5%-PBS-
Tween 0,5%, exceptions for phosphorylated ones that were diluted in bovine serum 
albumin (BSA) 4% and for RhoE antibody that was diluted in both solvents. In the next 
day the membrane was washed with PBS-Tween 0,5% and incubated with secondary 
antibody against mouse, rabbit or goat species (sheep anti-mouse immunoglobulin G 
(IgG) Horseradish Peroxidase linked (HRP) (GE Healthcare), donkey anti-rabbit IgG-
HRP (GE Healthcare), donkey anti-goat IgG-HRP (Santa Cruz Biotechnology), 
respectively).  
 50 
Detection. After some washings the membrane was incubated with ECL Plus Western 
Blotting Detection Reagents (GE Healthcare) and, in a dark room, an Amersham 
HyperfilmTM ECL (GE Healthcare) was put in contact with membranes. After some 
seconds or minutes of exposure the film was revealed with a 1:5 diluted solution of 
Developer and replanisher (Kodak GBX), washed and then fixed with 1:5 diluted 
solution of Fixer and replanisher (Kodak GBX). When membrane reprobing was 
intended it was made a first washing with PBS1x for 15 minutes, then membrane was 
incubated for other 15 minutes with a soft stripping solution, which contains acetic acid 
instead of β-mercaptoethanol to better preserve proteins integrity and finally it was 
washed again for 15 minutes to remove that solution. 
Quantification. Protein bands were quantified through the Quantity One 1-D Analysis 
Software (BioRad). The background value was deducted on the value of each band. 
The final value corresponds to a normalization to the tubulin value of same the gel.  
Statistical analysis. Student's t-test was performed to compare the means of the 
different experiments. P values of 0,5 or less were considered. 
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Table IV – Characterization of the antibodies used in western blot. 
PROTEINS PRIMARY ANTIBODIES 
Name Molecular weight (KDa) Dilution Species Company/Reference 
Actin 45 1:1000 goat Sta Cruz Biot (#sc-1616) 
Akt (total) 60 1:1000 rabbit Cell Sign (#9272) 
Akt (ph) 60 1:1000 rabbit Cell Sign (#3787S) 
Bcl2 26 1:100 mouse Dako (F7053) 
Cyclin D1 38 1:500 mouse Sta Cruz Biot (#sc-20044) 
E-cadherin 135 1:1000 rabbit Cell Sign (#3195) 
ERK (total) 42/44 1:1000 rabbit Cell Sign (#9102) 
ERK(ph) 42/44 1:1000 rabbit Cell Sign (#4377) 
JNK (total) 46/54  rabbit Cell Sign (#9252) 
JNK (ph) 46/54 1:1000 mouse Cell Sign (#9255S) 
MLK3 (total) 95 1:1000 rabbit Sta Cruz Biot (#sc-536) 
MLK3 (ph)  95 1:1000 rabbit Upstate 
p21 21 1:250 mouse BD Biosciences (554228) 
p27 27 1:1000 rabbit Sta Cruz Biot (#sc-528) 
p38 (total) 43 1:500 mouse Cell Sign (#9212) 
p38 (ph) 43 1:500 mouse Cell Sign (#9216S) 
p53 53 1:1000 rabbit Cell Sign (#9282) 
PI3K p110α 110 1:1000 rabbit Cell Sign (#4249) 
PI3K p85α 85 1:2500 mouse BD  Biosciences (610046) 
PTEN 55 1:100 rabbit Sta Cruz Biot (#sc-6817-R) 
RhoE 27 - mouse Abcam 
ROCK I 160 1:500 mouse BD Biosciences (611137) 
α-tubulin 50 1:10000 mouse Sigma  
β-catenin 92 1:2000 rabbit BD Biosciences (610153) 
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2.6 Functional assays 
2.6.1 Proliferation assay 
The proliferation assay performed was based on the incorporation of 
Bromodeoxyuridine (BrdU), which is a thymidine analogue, during DNA synthesis 
(phase S of cell cycle). 2,5 x 105 cells per well were plated in 6-well plates, with or 
without coverglasses Ø10mm (Sofdan) (the evaluation of this assay by flow cytometry 
does not require coverglasses), and grown in the CO2 incubator at 37ºC. After 48h, 
10µM of BrdU stock solution were added and cells were then incubated for 1 hour at 
37ºC. After that, medium with BdrU was removed and cells were washed twice in 
PBS1x. From here two different procedures were undertaken to fix cells and stain them 
with anti-BrdU, because at the end proliferation levels were evaluated by different 
methods: immunocytochemistry and flow cytometry. 
 
Immunocytochemistry. Cells were fixed in paraphormaldehyde 4% for 30 minutes, 
followed by PBS1x washing. To denature DNA, HCl 2M was added for 20 minutes and 
then coverglasses were washed in PBS1x and in PBS-0,5% Tween20 – 0,05% BSA. 
Details about antibodies incubation characteristics are described in Table V 
Coverglasses were mounted on microscope slides with a drop of Vectashield Mounting 
Medium with DAPI (Vector Laboratories, Inc.), covered with a coverslip (BioSigma) and 
counted on the microscope DM2000 (Leica) at 400x magnification. 
Flow cytometry. Cells were detached with trypsin-EDTA (Gibco, Invitrogen), 
resuspended in medium and the content was centrifuged twice at 1500rpm for 5 
minutes with an intermediate washing in PBS1x. Cells were then fixed with 70% 
ethanol in PBS1x for 30 minutes. After fixation procedure, cells were centrifuged again 
in the same conditions to remove fixation solution. After washing in PBS1x with 0,5% 
BSA cells were resuspended and 2M of HCl was added for 20-30 minutes to denature 
DNA. After new centrifugation the pellet was dissolved and incubated with primary and 
secondary antibodies in conditions described in Table V. Samples were read by Epics 
XL-MCL™ Flow Cytometer (Beckman Coulter) and analysed with WinMDI 2.9 
software.  
 
The viable cell population was delimited through the definition of a gate in a dotplot, 
where the events were distributed by size (forward scatter) and complexity (side 
scatter). Inside that gate, definition a new gate to select the singlet population was 
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created in a dotplot, where propidium iodide (PI) fluorescence was represented. Based 
on another dotplot containg both BrdU and PI fluorescences three regions were 
created corresponding to G0, S and G2/M phases and a final histogram was created 
(where M1 includes G0 and G2/M phases, and M2 includes S phase). 
Table V – Antibodies used in proliferation assay. 
Antibody Designation Dilution Incubation  
Primary  Monoclonal Mouse Anti-BrdU (Dako) 
1:10 PBS-0,5%Tween20 – 
0,05% BSA 
1h 
Secondary  
Polyclonal Rabbit Anti-Mouse IgG/FITC 
(DakoCytomation) 
1:100 in PBS-0,5%Tween20 – 
0,05% BSA 
30 minutes 
in the dark 
2.6.2 Migration assay 
Cells were plated, in duplicates, in 12-well plates until confluence. When they reached 
it, a pipete tip was used to make a scratch in the monolayer of cells. Immediately after 
that, in only one of the plates, ROCK inhibitor – Y27632 was added at a final 
concentration of 10µM, after removing the medium. Cell migration was photographically 
recorded in an automated way during 14 hours in time-lapse (Zeiss). Photos were 
taken each 5 minutes at 20x magnification. Films were analysed with Lsmib software 
(Zeiss). Cell migration was measured as the distance from the monolayer wall to the 
leading edge of the wound in three aleatory positions. 3x104 cells per well were also 
plated in a 24-well plate. After a few hours ROCK inhibitor was added to some wells to 
evaluate its action on cells morphology (comparative photos were taken). 
2.6.3 Viability assay 
This assay was performed in triplicate in 96-well plates. 4x103 and 8x103 cells were 
plated in each well (both in duplicates in each plate). In the next day, the medium was 
replaced by medium with 1% FBS instead of 10% as usually, in half of the wells. After 
8, 24 and 48 hours, 20µL of the MTS reagent from CellTiter 96® AQueous One 
Solution Cell Proliferation Assay (Promega) was added to each well. After these time-
points cells were incubated at 37ºC for 1–4 hours in a humidified, 5% CO2 atmosphere 
and absorbance was recorded at 490nm using a 96-well plate reader (BioRad). The 
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cell morphology was documented using an inverted bright field microscope, at 8 and 24 
hours upon culture with 1% FBS. 
2.6.4 Slow aggregation assay 
A slow aggregation assay was performed for HEK293 stable cell lines, using MCF7 
cells as a positive control and CHO cells as the negative one. Three replicas per 
sample were performed. 
 
Each well of a 96-well plate was coated with 50µL of agar medium previously prepared 
(100mg Bacto™ Agar (BD Biosciences) were dissolved in 15mL of PBS1x, that was 
boiled three times to sterilize the solution). This agar layer prevents cell-substratum 
adhesion. After its gelification, 100µL of a single-cell suspension (1x105 cells/mL) was 
seeded onto the semisolid agar of each well. Cultures were incubated for 44 hours in a 
humidified atmosphere of 5% CO2 in air at 37ºC. The aggregate formation was 
evaluated with an inverted microscope (40x magnification) after 15, 22 and 44 hours of 
incubation.  
2.7 Solutions recipes 
Table VI - Recipes of the solutions used in this experimental work. Distillated 
water was the solvent used. Solutions pH was measured with sympHony 
Multiparameter Research Meters SB90M5 (VWR). The pH was adjusted to the 
desired value with HCl 4M (Merck) and NaOH 5M (Merck). 
Solution Components pH Storage 
Bromophenol blue 6x 80µl 
Xylene blue 6x 80µl DNA ladder 
DNA marker 100µl 
- 4ºC 
Tris-HCl  0,5M  0,25M 
C3H8O3 (glycerol) 40% Laemmli Buffer4x 
SDS 0,319M 
6,8 -20ºC 
NaCl 2,74M 
KCl 54nM 
PBS stock solution 
20x 
Na2HPO4.2H2O 0,145M 
7,4 room 
temperature 
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KH2PO4 35mM 
C4H11NO3 HCl (Tris HCl)  50mM 
NP-40  1% 
NaCl  150mM 
RIPA buffer 
EDTA  1,65mM 
7,5 4ºC 
C4H11NO3 (Tris)  1,5M 
Separating buffer 
SDS 10% 0,4% 
8,8 
room 
temperature 
Separating buffer 24,8% 
Solution d´acrylamide 33% 
TEMED 0,2% 
Separating gel 
(10% acrylamide) 
Persulfate d´ammonium 10% 1% 
- 
prepared when 
used 
Acetic acid  10% 
Soft stripping solution 
Methanol  
 
10% 
- 
room 
temperature 
C4H11NO3 (Tris) 0,5M 
Stacking buffer 
SDS 10% 0,4% 
6,8 
room 
temperature 
Stacking buffer 20,6% 
Solution dácrylamide 13,22% 
TEMED 0,2% 
Stacking gel 
Persulfate d´ammonium 10% 0,99% 
- 
prepared when 
used 
C4H11NO3 (Tris-base) 0,87M 
H3BO3 (boric acid)  0,89M 
TBE 10x stock 
solution 
EDTA 0,5M pH=8 2mM 
8,0 
room 
temperature 
C4H11NO3 (Tris-base) 0,48M 
Transfer Buffer10x 
C2H5NO2 (Glycine) 0,39M 
- 
room 
temperature 
Transfer buffer 10x 10% 
Transfer Buffer1x 
Methanol 20% 
9,2 
room 
temperature 
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3 Chapter 4     Results and Discussion 
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3.1 P252H has functional value in colorectal context 
In 2010 MLK3 missense mutations were described for the first time by our group in 
colorectal carcinomas and protein predictive models, in vitro and in vivo experiments 
demonstrated that these mutations were functionally important. One of the described 
MLK3 mutations (P252H) became especially important, not only because it was shown 
to be associated to an aggressive phenotype, but also because it was constitutionally 
present in a colorectal cell line (RKO). That gave us the possibility to determine the role 
and the signalling pathways associated to this MLK3 mutation in its specific context. In 
order to access the functional role of MLK3 P252H in colorectal cancer, we transiently 
transfected RKO cell line with siRNA. RKO presents two MLK3 alleles, a wild-type 
MLK3 allele and P252H mutation. Furthermore, it presents multiple genetic alterations 
and that is a clear limitation in our study. However, taking this problem in consideration 
we proceeded with our study and transfected RKO with siRNA for the MLK3 mutated 
allele. 
 
The specificity of the siRNA to inhibit only the mutated allele and not the wild-type allele 
too, was confirmed by snapshot analysis (Graphic 1). So, any data that comes from 
this condition is only due to the inhibition of the P252H allele. 
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Graphic 1 - Snapshot results representing the allelic mRNA ratio. The values are 
normalized to GAPDH. The ratio between two alleles in both lipofectamine and siRNA controls 
was similar. However, in the third condition we verified a higher level of the wild-type allele 
comparing to the mutated one, what was in accordance with what we expected. 
 
We also confirmed MLK3 protein inhibition, by western blot, and evaluated the effect of 
the mutation in some targets: phosphorylated ERK, cyclin D1 and p21. The mutation 
appear to be downregulating these targets (Figure 13). 
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Figure 13 - Effect of P252H inhibition in expression levels of some proteins. The values 
are normalised to siRNA control. A) MLK3. B) phERK (note that this antibody was only tested 
once, that is why the bar in graphic does not have standard deviation). C) cyclin D1. D) p21.  
 
With these experiments, we could prove that P252H inhibition in colorectal cancer 
context interferes with targets related to the MAPKinase and WNT pathway. However, 
we also aimed to verify if the silencing of P252H lead to a decrease in RKO 
proliferation rate. In order to study this hypothesis we performed proliferations assays 
with BrdU incorporation more than once, but the presented data (Graphic 2) results 
only from a unique transfection that conjugates information from snapshot, western blot 
and proliferation assay.  
 
In spite to what has been previously shown for wild-type MLK3 silencing prevented 
serum-stimulated cell proliferation [37], and confirmed in our previous results, P252H 
silencing does not seem to have the same effect. It seems that alterations on the levels 
of the mutant protein on proliferation related targets is not reflected in the proliferation 
rate of the cells where P252H allele was inhibited. However, we need to confirm this 
result by performing again a new siRNA transfection followed by a snapshot analysis 
and a western blot to confirm the efficiency of the inhibition before performing the 
proliferation assay.  
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Graphic 2 - Results from proliferation assay in RKO transfected with either siRNA control 
or siRNA MLK3 P252H. BrdU-positive cells were counted and the value was normalised to 
siRNA control. 
Overall, we demonstrated that P252H mutation perturbs the expression of some 
targets in colorectal cancer cells thus this MLK3 mutation harbours a functional value 
and not a by passenger effect. 
3.2 Establishment of HEK293 stable cell lines 
After proving the functional value of P252H, it was important to evaluate the associated 
cellular effects per se and the signalling pathways that this MLK3 mutant could be 
affecting. To do so, we established MLK3 mutant stable cell lines. In order to have a 
clear cellular model, without multiple genetic alterations that could mask the function of 
MLK3 we choose HEK293 cell line and transfected it with MLK3 mutations (P252H and 
R799C), Mock vector and wild-type MLK3. As P252H and R799C MLK3 mutants were 
the most in vitro transforming mutations [11] and were also localized in two distinct key 
functional domains (the kinase and the P/S/T rich domains, respectively) we had a 
chance of studying genotype-phenotype correlations. In fact we aimed at verifying 
whether mutations in MLK3 localized in distinct domains lead to distinct or similar 
cellular effects and activated signalling pathways. Further, the wild-type MLK3 vector 
will allow us to understand if wild-type MLK3 overexpression causes the same effects 
as mutations do. At the same time it could also give us a hint about what happens in 
many tumours, where MLK3 protein was found to be overexpressed. 
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3.2.1 Selection after sequencing 
After transfection, HEK293 cells were subjected to a blasticidin selection, allowing the 
resistant ones, those with the vector, to survive. However, to guarantee that every 
replica had the right sequence in their vector, MLK3 gene was sequenced in all 
samples. The entire coding sequence of MLK3 (ENSG00000173327 – Appendix I) was 
screened for mutations. HEK293 MLK3 R799C was the first HEK293 stable cell line to 
be sequenced together with the parental one. Its MLK3 sequences were analysed in 
both DNA and cDNA.  
 
Some silent mutations were detected only in the cDNA of HEK293 MLK3 R799C T1 
(Figure 14) and because of that this replica was excluded from further experimental 
works. 
A                                                       B
T   T  C
 
Figure 14  – Examples of two unexpected mutations in R799C T1. A) The sample contains a 
–C-to-T substitution, localized at nucleotide position number 835, which does not alter the 
aminoacid phenylalanine localized at aminoacid position number 114 (code number in 
PUBMED´s protein database CAI94235). B) There are two peaks at nucleotide position number 
1021. The nucleotide C is the right one and the nucleotide T, that appears in heterozigoty, is a 
silent mutation, thus not alter the aminoacid isoleucine at aminoacid position number 176. 
R799C T2 and R799C T3 had the desired mutation correctly inserted, comparing to 
wild-type sequence 
 
Until here, the entire coding sequence of MLK3 was screened for mutations either in 
DNA or cDNA of MLK3 R799C stable cell lines. However, contrarily to what happened 
in cDNA, as in the DNA there were not found any mutations, we decided to screen for 
mutations only the cDNA of the other established stable cell lines, thus we were able to 
detect any mutation that could appear.  
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In P252H T2 we identified a deletion in the sequence between nucleotide position 
numbers 2366 and 2695 (Figure 15). Instead of the normal 330bp sequence there were 
only 13bp, without any identified homologue sequence. So, P252H T2 was also 
excluded. 
 
A B
330bp deletion
P252H
BlankT1 T2 T3
300bp
650bp
 
Figure 15 - Deletion in P252H T2. A) Agarose gel electrophoresis of PCR products from MLK3 
exon 9 amplification of P252H replicas. The expected band had 602bp size and the one below, 
near 300bp, corresponds to a deletion in P252H T2. B) Confirmation of P252H T2 deletion by 
sequencing the lower band. 
Those mutated stable cell lines that were not excluded presented the right insertion of 
the expected mutations (Figure 16).  
A.
WT P252H WT R799C
B.
 
Figure 16 - Correct insertion of the mutations into the MLK3 sequence. A) Comparison 
between MLK3 sequences from wild-type MLK3 and MLK3 P252H cell lines. B) Comparison 
between MLK3 sequences from wild-type MLK3 and MLK3 R799C cell lines. 
The Mock vector was also sequenced to confirm that there was not any undesired 
sequence in it.  
3.2.2 Selection based on transfection efficiency 
The level of transfection efficiency corresponded to the amount of protein expressed, 
which was evaluated by western blot analysis. From the previous step of selection we 
excluded two mixs of clones, each of one from a stable cell line with a different 
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mutation. To further perform comparative studies between wild-type MLK3 and mutant 
MLK3 it was imperative to determinate eventual expression gaps between replicas that 
could justify eventual differences in cellular effects. The results of the first western-blot 
for MLK3 expression are shown in the Graphic 3. As what was expected, Mock cell line 
had the lowest MLK3 expression. However, wild-type MLK3 stable cell lines had some 
differences of expression between them. So, from the graphic we excluded WT T2 
because we could not pare its MLK3 expression levels with those of any mutation. 
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Graphic 3 - MLK3 protein expression levels from the first western-blot after HEK293 
transfection. Bands quantification was done with Quantity One software. 
From now on and due to the similarity of MLK3 expression levels and also to simplify 
the data, the results will be presented in the following manner:  
- Wild-type (average value between T1 and T3 transfections) will always be 
compared to Mock, allowing the evaluation of the effect of wild-type MLK3 
overexpression; 
- The P252H mutation (average value of T1 and T3 transfections) will always be 
compared with WT T3 (abbreviated to WT), allowing the evaluation of the effect 
of P252H mutation in comparison to wild-type MLK3; 
- The R799C mutation (average value of T2 and T3 transfections) will always be 
compared with WT T1 (abbreviated to WT), allowing the evaluation of the effect 
of R799C mutation in comparison to wild-type MLK3. 
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3.3 Cellular effects of MLK3 mutations and of wild-type MLK3 
overexpression 
3.3.1 Proliferation 
In order to evaluate the effect of the mutant forms of MLK3 in comparison to wild-type 
MLK3 on proliferation rate, the stable transfected HEK293 cell lines were studied and 
performed a BrdU immunocytochemistry. According to the Graphic 4 no differences 
were found between the proliferation rates of P252H and R799C, when compared with 
the respective wild-type control. However, the meaning of this result is still debatable 
since we only performed a single experiment and this was due to a technical limitation. 
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Graphic 4 - Proliferation rate of MLK3 mutations compared to the respective WT. 
HEK293 cells have very low adherence to coverslips and consequently a very low 
number of cells per coverslip is obtained in the end of an immunocytochemistry, thus it 
was difficult to repeat this experience. As an alternative approach we evaluated the 
proliferation by flow cytometry (Figure 17). However, the results seem to confirm the 
previous ones, no significant differences were found between mutations and their 
respective wild-types or between wild-type and Mock. Both results suggest that MLK3 
does not play a major role in cell proliferation control.  
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Mock                                          WT
A.
 
WT                                        P252HB.
 
WT                                                              R799CC.
 
Figure 17 - Histogram representation of the cell cycle of HEK293 stable cell lines. It shows 
the number of cells in G0, G2/M phases (M1) and S phase (M2). Comparisons between WT and 
Mock (A), P252H mutation and respective WT (B) and between R799C and respective WT (C). 
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3.3.2 Viability 
The viability assays performed allows the determination of the number of viable cells in 
proliferation or cytotoxicity effects and consists in the reduction of a tetrazolium 
compound named MTS into the colored formazan product [92]. This conversion is 
presumably accomplished by NADPH or NADH produced by dehydrogenase enzymes 
in metabolically active cells [93]. The quantity of formazan product formed is measured, 
after 1-4 hours of the addition of the reagent, by the absorbance at 490nm and is 
directly proportional to the number of living cells in culture. So, this assay allows the 
indirect measurement of viable cells in culture. 
 
The manufacturer advices to first perform a cell titration to choose an optimal cell 
number of cells to initiate the assay. They also recommend an initial number of 5000 
cells per well to initiate proliferation studies with most tumour cells, hybridomas and 
fibroblast cell lines. In our study we only tried two different initial conditions: 4000 and 
8000 cells per well. 
 
Graphics A, B and C from Figure 18 shows the absorbance at 490nm of HEK293 
stable cell lines (Mock, wild-type MLK3, P252H, R799C) upon 8(A), 24 (B) and 48 
hours (C) of culture with either 10% FBS or 1% FBS, which is directly proportional to 
the number of living cells in culture. The increased absorbance observed along time in 
any stable cell line was independently on the percentage of FBS in culture and could 
be attributed to an increase in the number of cells and not to an increase in cell 
viability. Anyway, this indicates that 1% FBS is not affecting cell metabolism to a great 
extent and that a stronger stimulus must be used to provoke a decrease in cell viability 
along time. 
 
Now, looking at the absorbance values of cells exposed to 1% FBS after 8 and 24 
hours we realize that sometimes they are similar or even higher than those grown with 
10% FBS. Values are not yet stabilized and that increase could probably be attributed 
to an adaptation process. It is known that nutrient deprivation causes an upregulation 
of NAD+ levels in mitochondria, which determines cell survival [94].  
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Figure 18 - Cell viability of HEK293 stable cell lines, upon 8 (A.), 24 (B) and 48 hours (C) 
of culture with either 10% FBS or 1% FBS. 
Figure 19 shows the influence of 48 hours of culture with 1% FBS on cell viability, with 
either 4000 or 8000 cells per well, as initial conditions. As proliferation does not seem 
to be altered, the observed differences between stable cell lines, upon treatment wit
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1% FBS, should not be attributed to differences in proliferation rate. In both initial 
conditions, wild-type MLK3 overexpression itself caused a decrease of almost 20% in 
cell viability and R799C mutation presented viability values lower than wild-type control 
in graphic I, but similar in graphic II. In cells expressing P252H mutation it is not very 
clear if the mutation provokes a decrease in cell viability or not, because the standard 
deviations are too big. Such big standard deviations could be due to mistakes in the 
number of cells plated in each well. However, this MLK3 mutant seems to be more 
resistant, at least to 1% FBS, than the other mutant.  
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Figure 19 - The effect of culture with 1% FBS and wild-type MLK3 overexpression (A) or 
MLK3 mutations (B) on viability of two different initial conditions (I – 4000 cells per well; 
II – 8000 cells per well). The values are normalised to the control either to Mock 10% FBS (A) 
or to WT 10% FBS (B)). Cells were incubated in normal culture conditions in the presence of 
10% FBS (graybars) or presence of 1% FBS (black bars) for 48 hours. After treatment, the MTS 
reduction assay was used to determine the level of cell survival, compared with controls.  
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Upon 48 hours of culture, cells subjected to 1% FBS not only dye more than those 
grown with 10% FBS as they develop a different morphology. Looking only to pictures 
of cells treated with 1% FBS for 48 hours (Figure 20) we observe that MLK3-mutated 
and Mock cells present a round-shape morphology with reduced area, losing the 
majority of the cellular extensions, while wild type cells retained their morphology, with 
differences in cell number.  
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Figure 20 - Cells morphology after 24 and 48 hours of culture with either 10 or 1% FBS 
(data from an initial number of 4000 cells per well). (A) Mock pictures; comparisons between 
(B) P252H and WT, (C) R799C and WT. 
In spite of the well accepted number of replicas used per each stable cell line, which 
indeed increases the reliability of the results, this assay was only performed once. In 
future experiments it must be followed by a western blot analysis to evaluate the 
expression of some apotosis and proliferation-related proteins, such as Bcl2 or capase-
 71 
3 and cyclin D1 or p21. Depending on the type of stimulus applied, both P252H and 
R799C mutations may confer different resistance to cells. However this should be 
proven, subjecting cells to more aggressive stimuli. More cell numbers in the beginning 
of the assay have also to be tested to take more clear conclusions about, at least, the 
effect of P252H mutation on cell viablity. To complement these studies in the future cell 
death should be also evaluated by flow cytometry, using annexin V. 
3.3.3 Migration 
Cell migration was recorded for 14h. After that, both WT seem to have differences in 
the establishment of cells protrusions, because WT T1 presents more and longer 
protrusions than WT T3 (Figure 21). This effect may be related to the level of 
expression of wild-type MLK3 since WT T1 and WT T3 present different levels of MLK3 
protein expression. However, this hypothesis needs to be proven by additional 
experiments. 
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Figure 21 - Photos of migration assay at 0 and 14 hours. (A) Mock cells. Comparisons 
between (B) P252H and WT, (C) R799C and WT. 
Data resuming the measures made in every films are presented in Figure 22. 
Interestingly, the mutation R799C leads to an impairment of cell migration levels, 
comparing to WT. Otherwise, P252H mutation seems to have the opposite effect. The 
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overexpression of wild-type MLK3 also leads to an increase in cell migration levels, 
comparing to Mock. The differences in the migrated distance should not be attributed to 
differences in cell proliferation since the proliferation rate of mutant MLK3, wild-type 
MLK3 and Mock cells were very similar (results presented above). 
 
Migration assays could have been better explored. For instance, to guarantee that any 
observed effect was due to cell proliferation, we could prolong the assay for 24 hours 
using mitomycin-C, which inhibits cell proliferation [75]. To minimize the eventual effect 
on cells communication of the different wound sizes created by manual scratching we 
could experiment the CytoSelect™ 24-Well Wound Healing Assay (Cell Biolabs), 
where defined wound fields are created. However, the results can not be directly 
compared since in the case of CytoSelect™ 24-Well Wound Healing Assay there is not 
cell damage and that the lack of this damage stimulus could alter the results.  
 
The velocity of migration is another important parameter that we could also evaluate.  
The distance migrated along time could be graphically represented, given the idea of 
migration or contraction of cells from the monolayer. Indeed cells trajectories could also 
be evaluated in cells plated with lower confluence. Together these data would bring 
valuable clues to better understand the observed differences in the distance migrated 
by HEK293 stable cell lines. 
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Figure 22 - Migrated distance by each HEK293 stable cell line after 14 hours. Cell 
migration was calculated by subtracting the leading edge distance from the starting position of 
the leading edge. (A) MLK3 WT versus Mock, (B) MLK3 mutants versus MLK3 WT. 
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3.3.4 Aggregation 
In general, cell aggregation assays are designed to test the functionality of cell to cell 
adhesion and indirectly to access the status of the E-cadherin/catenin complex. Cell-
cell adhesion is mostly dependent on the integrity of this complex. This assay allows to  
study the capacity of the cells to adhere to the neighbouring cell in a cohesive status 
[95]. In slow aggregation assays cells are seeded on a semisolid agar substrate in a 
96-well plate and the cells spontaneously aggregate. 
 
As a negative control for this experimental assay CHO cells were used since these 
cells are cadherin-negative and fail to aggregate homotypically, despite forming a 
single central cluster. MCF7 cells were used as a positive control since they express E-
cadherin and make multiple and disperse aggregates around the well. The level of 
aggregation was photographically registered at different time points (Figure 23A).  
 
At 15 hours, there were differences in the pattern of slow aggregation between Mock 
and all the other stable cell lines. Mock cells already presented a large, compact and 
central-positioned aggregate, while the other stable cell lines do not present a cohesive 
one (Figure 23B-D). At 22 hours those differences were a bit attenuated. Mock cells 
developed a perfect round-shaped aggregate while the other stable cell lines are 
acquiring that phenotype in a slower way. At 44 hours all stable cell lines present a 
similar pattern of aggregation, despite the delay observed in wild-type and mutated 
cells in the initial time points. 
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Figure 23 - Cell aggregation captured at different time points: 15, 22 and 44 hours with an 
initial cell number of 10000cells per well. (A) CHO and MCF7 cells, (B) Mock cells; 
comparisons between (C) P252H and WT, (D) R799C and WT. 
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This type of aggregation assay has a great disadvantage, because it only provides us 
qualitative information. To overcome this limitation in future experiments we could 
perform a “fast” aggregation assay that allows quantification analysis and that is pivotal 
to evaluate the initial phases of cell aggregation, where we found the biggest difference 
between Mock and the other stable cell lines. 
3.4 Signalling of P252H and R799C mutations and of wild-type 
MLK3 overexpression 
In Figure 24 we present a brief summary of the western blots performed to evaluate the 
levels of protein expression of some important targets of MLK3 or of other proteins that 
could also be affected by MLK3. Most of the values presented are tendencies and not 
definitive conclusions since some of these results need to be repeated to get definitive 
conclusions. This confirmation in some cases was not possible due to the limitation of 
the time to present this thesis. However, we decided to include them since some 
results could be interesting for discussion, even knowing that they need extra 
confirmation. 
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Figure 24 - Western Blot analysis in HEK293 stable cell lines. 
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After performing the western blots, protein expression levels were analysed with 
Quantity One software and the final results are summarized in Table VII. 
Table VII - Expression levels of the proteins tested by western blot. An 
increase or a decrease in protein expression was only considered when there was, 
at least, a difference, of 1,2 fold comparing to control. Many protein quantifications 
here presented have an interrogation point (?) because there are some doubts in 
the final result, which requires new experiments. 
Function Protein P252H R799C WT 
Cyclin D1  ↓ 1,7x   (p<0,05) ↑ 4x   (p<0,05) ↑ 3x 
Cell cycle 
p27  ↓ 1,3x ↑ 2,3x ↓ 1,3x 
phMLk3  ≈  ↑ 1,6x ? 
phJNK  ↑ 1,7x ? ↑ 1,3x ? ≈ ? 
JNK  ↑ 1,2x  ≈? ≈ ? 
p53  ≈ ≈? ↑ 1,5x 
ph p38  ↓ 1,5x ? ≈? ↑ 2,2x ? 
MAPK 
signalling 
 
 
 
 
 
p38  ? ? ↓ 1,5x 
PI3Kp110α  ↓ 1,3 x ? ↑ 1,2 x ? 
PI3Kp85α  ≈ ? ≈ ? ≈ 
phAkt  ↑ 1,2 x  ≈ ≈ 
Akt  ≈ ? ↑ 1,4 x ? ≈ ? 
PTEN  ≈ ? ≈ ? ≈ ? 
Survival 
Bcl2  ↓ ≈  ? ≈ ? ≈ ? 
ROCK I  ↑ 1,5 x   (p<0,05) ≈ ? ≈ ? 
E-cadherin  ↓ 1,3 x  ↓ 1,6 x ≈? 
β-catenin  ≈ ≈ ? ≈ ? 
Adhesion/ 
migration 
RhoE  ↓ 1,6 x ? ↑ 1,3 x ? ↑ 2,7 x ? 
 
A detailed description of some important quantifications will be reported below, as well 
as its association with the cellular effects already presented, whenever possible. 
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3.4.1 MLK3 mutations induces invasion by E-cadherin regulation 
The disturbance of intercellular adhesion is one key event for the release of invasive 
cells from carcinomas [96]. This may be accomplished by loss of function or expression 
of the epithelial cell-adhesion molecule E-cadherin, which is observed during tumour 
progression of most carcinomas, and through the activity of cell motility factors [97]. 
The observed decrease in E-cadherin expression in HEK293 cells expressing R799C 
and P252H mutations (Table VIII) corroborates the previous data from our group that 
show the ability of both MLK3 mutant tumours to invade the surrounding adipose tissue 
and muscle, in contrast to the positive control H-RasV12-expressing tumours [11]. 
However, based on a higher decrease in E-cadherin expression in R799C we still 
cannot explain why P252H mutation showed the most aggressive behaviour, with 
invasion of backbone, bone marrow and spinal cord, but of course, we must take into 
account many other important factors. This effect may be due to differences in cell 
migration, since P252H shows an increased migration potential in comparison to 
R799C. 
Table VIII - Information about E-cadherin protein expression levels of MLK3 
mutants. 
Protein P252H R799C 
E-cadherin ↓ 1,3x ↓ 1,6x 
 
3.4.2 P252H and R799C mutations do not share similar patterns of 
p27 and cyclin D1 expression  
P27 is a cyclin-dependent kinase inhibitor (CDKI) that belongs to the Cip/Kip family, 
which also includes p21. Quiescent cells present an increase in p27 protein levels, 
which is rapidly inverted after stimulation with mitogens (rewiew in [98]). The most well-
known function of p27 is its binding to cyclin E/CDK2 complex and consequently 
inhibition of this kinase activity. However, p27 role is not only restricted to cell cycle 
regulation. In fact, in normal human colonic mucosa or during colorectal 
carcinogenesis, the relation between p27 expression levels and cell proliferation was 
excluded [99]. In our study the alterations in p27 expression levels also do not seem to 
be associated to cell proliferation, whereas all stable cell lines have similar proliferation 
rates. 
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In an interesting study authors showed that down-regulation or loss of p27 was found 
to occur significantly associated to metachronous metastases, and not to primary 
colorectal adenocarcinomas, indicating a role for p27 in the development of metastasis 
and consequently on the late stages of progression of colorectal cancer [100]. This 
reduction of p27 levels was also found in advanced gastric cancer. Advanced gastric 
cancer presented a p27 reduction of about 41% against 15,6% in early gastric cancer 
[101] . In our study, cells expressing P252H mutation presented low levels of p27 when 
compared to cells expressing wild-type MLK3 (Table IX). This is an interesting result 
since it may explain the worse behaviour of this mutant and its ability to invade the 
bone marrow. As it is established that low p27 expression correlates with worse 
prognosis, some clinical trials are already taking into account an evaluation of p27 
expression, through immunohistochemistry, in advanced solid tumours, upon treatment 
with specific drugs. (ClinicalTrials.gov NCT00388089 and NCT00389805). Strategies to 
increase p27 levels will probably bring good results to cancer therapy. 
Table IX - Summary of results from proliferation assay and from both p27 and 
cyclin D1 protein expression levels of MLK3 mutants. 
 P252H R799C 
Proliferation assay ≈ ≈ 
Cyclin D1 ↓ 1,7x (p<0,05) ↑4x (p<0,05) 
p27 ↓ 1,3x ↑2,25x 
 
However, a total distinct cellular phenotype is expected when p27 shows an increased 
level of expression as verified for the MLK3 mutant R799C. In fact, it was suggested 
that high levels of p27 expression may suppress metastasis in colon cancer cells [102]. 
P27 overexpression in HT29 colorectal cancer cell line leads to partial growth inhibition 
when compared to those of control vector clones [102]. Authors also observed an 
increase in sodium butyrate induced-differentiation by counting cells positive for the 
enzyme intestinal alkaline phosphatase [99], which is a well-known marker of 
differentiation in HT29 cells and other colon cancer cell lines [102, 103]. In order to 
determine if that p27 overexpression was affecting other cell cycle related proteins the 
authors investigated other cyclins and CDKs [102]. As expected the kinase activity of 
E/CDK2 complex was lower, but interestingly among other proteins, only cyclin D1 
 80 
expression was altered, from about 1.9 fold to 3.6-fold increase in its expression levels, 
what may suggest the existence of a feedback loop between p27 and cyclin D1 [102]. 
 
Interestingly, we also found a tight correlation of p27 and cyclin D1 in our MLK3 
mutants. In one hand, cells expressing the R799C MLK3 mutation display high levels of 
p27 and cyclin D1 (Table IX). This positive correlation was already identified in some 
human breast cancer cells and adenomatous polyps [99, 104]. On the other hand, 
P252H MLK3 mutant displays low levels of p27 and cyclin D1 (Table IX). Interestingly, 
when an antisense cyclin D1 cDNA construct was overexpressed in the human colon 
cancer cell line SW48OE8 it led to a decreased expression of p27 [105]. 
 
Furthermore, it was already established a correlation between p27 expression and 
tumour grade; i.e., tumours high p27 expression are well or moderately differentiated 
carcinomas, whereas tumours with lower p27 expression are poorly differentiated 
carcinomas [99]. Together these data bring new insights that both MLK3 mutations 
studied (P252H and R799C) followed different pathways towards cancer. R799C 
mutation may be related to differentiation, while P252H may confer other important 
properties such as promotion of cell migration.  
 
There are some other evidences that may corroborate these findings (results not 
published). Although we did not evaluated the protein levels of BMP-6, our group 
showed that BMP-6 gene seems to be 1,7 fold up-regulated in cells expressing R799C 
mutation when compared to cells expressing P252H that show a decreased of 1,4 fold 
down-regulation of BPM-6. BPM-6 is known to positively regulate the differentiation of 
primary skin keratinocytes grown in culture and among other BMP is a potent regulator 
of osteoblast differentiation [106, 107]. 
 
Of course, to validate our hypothesis, that the different MLK3 mutants regulate colon 
differentiation in a distinct manner we need to evaluate the expression of markers, such 
as vimentin in HEK293 cells pellet embedded in paraffin, through the search of 
epithelial markers, such as CD10, BerEP4, cytokeratin (CK) 7, CK-Cam5.2., CK18 as 
already performed by Nalvarte and collegues [108]. 
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3.4.3 P252H mutation induces cell migration  
Curiously MLK3 inhibition, through siRNA, decreases ROCK expression levels, 
meaning that these two proteins are somehow related (Figure 25).  
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Figure 25 - Western blot analysis of MLK3 and ROCK expression, upon MLK3 inhibition 
with siRNA, in HEK293 Mock stable cell line 
The Rho-associated coiled-coil forming kinase, ROCK, is one of two major effectors for 
Rho. This serine/threonine kinase phosphorylates a variety of substrates: myosin-
binding subunit of myosin phosphatase and myosion light chain, enchancing 
actomyosin contractility, and LIM-kinase that inactivates cofilin leading to filaments 
stabilization (review in [8]). Therefore ROCK has a crucial role in cell migration. 
 
Most reported data show that Rho/ROCK pathway-related proteins are related to 
cancer progression. In bladder cancer, for example, higher levels of RhoA, RhoC, 
ROCK-I and ROCK-II were found in tumour tissue with positive lymph nodes 
metastases when compared to non-tumoral tissue and primary tumours without lymph 
nodes metastasis [109], demonstrating that their level of expression was associated 
with poor differentiation, muscle invasion, lymph node metastasis and shortened 
survival. In breast cancer, Rho C overexpression was reported to be associated to an 
aggressive form of cancer and seems to have an important role on the production of 
angiogenic factors [110]. The data reported in these two tumour models, bladder and 
breast, plus our own (previously discussed) it seems that poor differentiated and 
aggressive carcinomas shows an increase in ROCK levels and a decrease in p27 
protein levels. 
 
In fact, we can suggest that MLK3 P252H mutation induces poor differentiated 
tumours, which is associated with its p27 and ROCK expression levels (Table X) and is 
reflected in a tumour with higher ability to migrate, as verified previously, and produces 
metastasis. But this hypothesis needs to be proven. 
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Table X - Summary of results from migration assay and from both ROCK and 
RhoE protein expression levels of cells expressing P252H mutation. 
 P252H 
Migrated distance  ↑1,3x 
ROCK ↑1,5x (p<0,05) 
RhoE ↓1,6x ? 
 
Besides the levels of ROCK I, we also determined the levels of RhoE for both MLK3 
mutants. RhoE interacts with ROCK I and inhibits ROCK I-induced actin stress fiber 
formation and myosin phosphatase phosphorylation. Thus, in MLK3 P252H mutation 
the results of both ROCK I and RhoE expressions are in agreement with the inhibitory 
effect of RhoE on ROCK (Table X) expression. Actualy, we verified that MLK3 P252H 
mutant induces low levels of RhoE accompanied by a significant increase in ROCK 
expression. To verify if, besides inducing ROCK expression levels, P252H mutation 
also induces Rho activity, it will be interesting to perform Rhotekin pull down assays 
(Cell Biolabs). 
3.4.4 R799C mutation decreases cell migration  
As mentioned in the introduction chapter, MLK3 limits activated Gαq signalling to Rho 
by binding to p63RhoGEF [66]. This interaction is induced by MLK3 phosphorylation on 
residues Thr277 and Ser281 and is inhibited by effects of the JNK pathway on MLK3, 
through a feed back loop [32].  
 
In cells expressing R799C MLK3 mutation, MLK3 phosphorylation is increased, what 
induces the downstream activation of JNK, as we may observe through an increase in 
phosphorylated JNK (Table XI). Although JNK may be affecting MLK3 levels in a 
feedback loop, its activation (only 1,3 fold increase) might not be enough to provoke 
the complete dissociation between MLK3 and p63RhoGEF and Rho may still activated. 
This explanation may justify the slight decrease in the distance migrated by these cells, 
when comparing to the control. However, phospho-JNK antibody has to be tested 
again. 
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Table XI - Summary of results from migration assay and from phospho-MLK3 
and phospho-JNK protein expression levels of cells expressing R799C 
mutation. 
 R799C 
Migrated distance  ↓1,3x 
Phospho MLK3 ↑1,6x 
Phospho JNK ↑1,3x ? 
 
3.4.5 Effects of ROCK inhibitor 
In order to verify if the migratory behaviour of cells was dependent on ROCK 
expression we studied the effect of ROCK inhibition in the MLK3 P252H mutation. Cells 
expressing P252H MLK3 mutant showed an increase in cell migration and presented 
the highest levels of ROCK. In contrast to what we expected, the distance migrated 
was not significantly affected by the ROCK pharmacological inhibitor Y27632 (Figure 
26). But this data has a clear technical limitation since we should have performed 
protein extract to confirm, by western blot, that ROCK was in fact being inhibited. It had 
also been interesting to evaluate MLK3 levels, upon ROCK inhibition, to better 
understand the relation between these two proteins.  
 
A.                                                             B.
0,00
200,00
400,00
600,00
Mock WT
M
ig
ra
te
d
 d
is
ta
n
c
e
 (
μ
m
)
wi thout ROCK i nhibitor with ROCK inhibitor
0,00
200,00
400,00
600,00
WT P252H WT R799C
M
ig
ra
te
d
 d
is
ta
n
c
e
 (
μ
m
)
without ROCK inhibitor with ROCK inhibitor
 
Figure 26 - Migrated distance by the different HEK293 stable cell lines either with or 
without treatment with ROCK inhibitor - Y27632. Comparison between (A) Mock and WT 
cells; (B) WT and MLK3 mutants cells. 
However, if we presume the the ROCK pharmacological inhibitor Y27632 was effective 
and the distance migrated was not significantly altered, we wonder what was being 
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affected by ROCK inhibition. To study the effect of ROCK inhibition on cell morphology 
we added Y27632 to cells at low confluence. Almost immediately after ROCK inhibitor 
was added we observed a complete alteration of the cells phenotype (Figure 27). This 
effect of ROCK inhibition on cell morphology was already described in the literature 
and showed to dramatically increase cell spreading and the number of lamellipodia 
around the perimeter of the cell [111, 112].  
 
Without ROCK inhibitor (0h)                               With ROCK inhibitor (0h)
M
o
ck
A
 
 
W
T
P
2
5
2
H
Without ROCK inhibitor (0h)                               With ROCK inhibitor (0h)
W
T
P
2
5
2
H
B
  
 85 
Without ROCK inhibitor (0h)                               With ROCK inhibitor (0h)
W
T
R
7
9
9
C
W
T
R
7
9
9
C
C
 
Figure 27 - Effect of ROCK inhibitor - Y-27632 on cells morphology. (A) Mock cells. 
Comparison between (B) WT and R799C, (C) WT and P252H. 
In summary and unlikely to what we hypothesized initially, ROCK inhibition did not 
affect the overall process of cell migration. This is not surprising since it is well known 
that migration is a very complex process resulting from the combination of different 
actions: myosin-actin contractability, G protein signaling, microtubule dynamics and the 
turnover of focal adhesions, thus, ROCK inhibition could only partially affected the 
overall process [113] 
3.4.6 MLK3 mutations and WNT signalling pathway 
WNT signalling pathway has been highly conserved during evolution. It is involved in 
embryonic development of all species, in the regeneration of tissues in adult organisms 
and in many other functions. In many cancers, namely in colorectal cancer components 
of this pathway presents either mutations or altered expression (review in [114]) 
 
Unpublished results from our group show that cells expressing P252H mutations have 
an upregulation of FZD10 (1,3 fold), while in cells expressing the MLK3 R799C 
mutation show a 1,2 fold down-regulation of FZD10 . High-levels of FZD10 mRNA 
expression occurs in different human cancer cell lines and seems to be related to the 
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activation of a non-canonical WNT/β-catenin signalling [115]. Cancer cells 
immunopositive for FZD10 showed significantly less nuclear accumulation of β-catenin, 
compared to FZD10-immunonegative cancer cells, what suggests that FZD10 has an 
important role in the switch of the canonical WNT signal transduction to a non-
canonical WNT pathway [116]. Furthermore, we also demonstrated that cells 
expressing MLK3 P252H mutation presents a decrease in LEF1 mRNA levels (data not 
yet published by the group). Down-regulation of LEF1 also inhibits WNT canonical 
pathway, suggesting again an induction of the non-canonical pathway, by cells 
expressing P252H  mutation [117]. Interestingly, it was also reported that whenever the 
non-canonical WNT pathway is activated there is ROCK activation followed by reduced 
levels of p27 protein [118]. In our experimental work, we verified the same tendency; 
cells expressing P252H MLK3 mutation present higher levels of ROCK protein and 
lower levels of p27 protein, suggesting that this MLK3 mutation induces a switch from a 
canonical WNT pathway to an activation of a non-canonical WNT pathway. 
 
In contrast, cells expressing R799C mutation present high levels of cyclin D1, what 
may suggest an activation of the WNT canonical pathway. However, it is important to 
confirm, by immunohistochemistry, that β-catenin expression is at the nucleus. 
 
Although a lot of questions remain to be answered, we can already summarize some 
important data by the following representation of the WNT pathway. P252H mutation 
induces activation of the non-canonical WNT pathway, while R799C mutation induces 
WNT canonical pathway activation (Figure 28). 
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Figure 28 - Schematic representation of WNT canonical and non-canonical pathways in 
which mutant forms of MLK3 may exert an effect (udapted from Saadeddin 09). For p27 
and ROCK we have only information regarding their protein expression levels. 
3.4.7 Wild-type MLK3 overexpression 
In HEK293 cells expressing wild-type MLK3 there is a tendency to an increased 
expression p53 (Table XII). Mutations of p53 occur in about 50% of all human tumours 
[119]. However, an increase of expression of wild-type p53 is associated to some kind 
of protection in response to various types of stress, such damages in DNA or mitotic 
spindle (reviewed in [119]). For instance, there is an increase in p53 after exposure of 
the skin to UV light, allowing DNA repair before replication that would make DNA 
damage permanent [120]. 
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Table XII - Summary of results from cell viability assay and from both p53 
and phospho-p38 protein expression levels of cells overexpressing wild-type 
MLK3. 
 WT 
Cell viability ↓1,2x 
p53 ↑1,5x 
Phospho -p38 ↑2,2x ? 
 
MLK3 overexpression seems to induce a decrease in cell viability, when comparing to 
Mock cells. This effect is very well described, mainly in neurons and in our particular 
case may be related to the observed increase of phospo-38 expression (Table XII). As 
p38 signalling is involve in response to stress stimulus, an up-regulation of this 
pathway could eventually lead to decrease in cell survival, upon a stimulus of FBS1%. 
This effect is probably related to an induction of apoptosis, however this suggestion 
requires confirmation. P38 indeed induces apoptosis, by regulating some proteins of 
Bcl-2 family. For instance it regulates the translocation of Bax, a pro-apoptotic protein, 
from cytosol to mitochondria, and also phosphorylates Bim, another pro-apoptotic 
protein, upon a variety of apoptic stimuli [121, 122]. 
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Chapter 5   Concluding remarks and future perspectives 
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This experimental work brings a new insight on the functionality of the MLK3 mutations 
P252H and R799C, but unfortunately it is not possible to take much defined 
conclusions yet. However, this work presents results that promote us to perform further 
research on the topic but now in a more focus manner. Due to the time constraints, we 
were not able to perform some experiments at least twice and to initiate other 
interesting ones that might corroborate our results. Thus, further studies are required in 
order to validate the results here presented. Some suggestions were already proposed 
in the previous chapter. 
 
In the first part we intended to prove the functional value of P252H mutation in a 
colorectal cancer context. Our results prove it, as observed by the down-regulation of 
some MLK3 targets, upon inhibition of P252H allele of RKO cell line. 
 
Secondly we established HEK 293 stable cell lines, expressing the wild-type MLK3 or 
MLK3 mutants. We wanted to verify a genotype-phenotype correlation that means that 
depending on the localization of MLK3 mutation the cellular effects and signalling 
pathways were different. The results suggested that MLK3 mutants behave 
differentially, inducing the activation of different signalling pathways. Both mutations 
are able to induce invasion, but only P252H may induce cell migration. This effect of 
P252H may be eventually more associated to an increased ability to induce a 
metastatic phenotype. R799C mutation seems to induce differentiation. These 
differences between both mutations may be explained by their possible differential 
activation of WNT signalling pathway. MLK3 mutations alter colorectal cancer 
developmental pathways and by this may also have a crucial role in tumourigenesis. 
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Appendix I - MLK3 sequence into pLENTI vector 
 
TCGTAACAACTCCGCCCCATTGA CGCAAATGGGCGGTAGGCGTG TACGGTGGGAGGTCTATATAAG
CAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGA
AGACACCGACTCTAGAGGATCCACTAG TCCAGTGTGGTGGAATTGATCCCTTCACC        ATG 
 
   481 V e c t o r  ATGGAGCCCTTGAAGAGCCTCTTCCTCAAGAGCCCTCTAGGGTCATG 
   541 GAATGGCAGTGGCAGCGGGGGTGGTGGGGGCGGTGGAGGAGGCCGGCCTGAGGGGTCTCC 
   601 AAAGGCAGCGGGTTATGCCAACCCGGTGTGGACAGCCCTGTTCGACTACGAGCCCAGTGG 
   661 GCAGGATGAGCTGGCCCTGAGGAAGGGTGACCGTGTGGAGGTGCTGTCCCGGGACGCAGC 
   721 CATCTCAGGAGACGAGGGCTGGTGGGCGGGCCAGGTGGGTGGCCAGGTGGGCATCTTCCC 
   781 GTCCAACTATGTGTCTCGGGGTGGCGGCCCGCCCCCCTGCGAGGTGGCCAGCTTCCAGGA 
   841 GCTGCGGCTGGAGGAGGTGATCGGCATTGGAG GCTTTGGCAAGGTGTACAGGGGCAGCTG  
   901 GCGAGGTGAGCTGGTGGCTGTGAAGGCAGCTCGCCAGGACCCCGATGAGGACATCAGTGT 
   961 GACAGCCGAGAGCGTTCGCCAGGAGGCCCGGCTCTTCGCCATGCTGGCACACCCCAACAT 
  1021 CATTGCCCTCAAGGCTGTGTGCCTGGAGGAGCCCAAC CTGTGCCTGGTGATGGAGTATG C 
  1081 AGCCGGTGGGCCCCTCAGCCGAGCTCTGGCCGGGCGGCGCGTGCCTCCCCATGTGCTGGT 
  1141 CAACTGGGCTGTGCAGATTGCCCGTGGGATGCACTACCTGCACTGCGAGGCCCTGGTGCC 
  1201 CGTCATCCACCGTGATCTCAAGTCCAACAACATTTTGCTGCTGCAGCCCATTGAGAGTGA 
  1261 CGACATGGAGCACAAGACCCTGAAGATCACCGACTTTGGCCTGGCCCGAGAGTGGCACAA 
  1321 AACCACACAAATGAGTGCCGCGGGCACCTACGCCTGGATGGCTCCTGAGGTTATCAAGGC 
  1381 CTCCACCTTCTCTAAGG GCAGTGACGTCTGGAGTTTTG GGGTGCTGCTGTGGGAACTGCT 
  1441 GACCGGGGAGGTGCCATACCGTGGCATTGACTGCCTTGCTGTGGCCTATGGCGTAGCTGT 
  1501 TAACAAG CTCACACTGCCCATCCCATC CACCTGCCCCGAGCCCTTCGCACAGCTTATGGC 
  1561 CGACTGCTGGGCGCAGGACCCCCACCGCAGGCCCGACTTCGCCTCCATCCTGCAGCAGTT 
  1621 GGAGGCGCTGGAGGCACAGGTCCTACGGGAAATGCCGCGGGACTCCTTCCATTCCATGCA 
  1681 GGAAGGCTGGAAGCGCGAGATCCAGGGTCTCTTCGACGAGCTG CGAGCCAAGGAAAAGGA  
  1741 ACTAC TGAGCCGCGAGGAGGAGCTGACGCGAGCGGCGCGCGAGCAGCGGTCACAGGCGGA 
  1801 GCAGCTGCGGCGGCGCGAGCACCTGCTGGCCC AGTGGGAGCTAGAGGTGTTCGA GCGCGA 
  1861 GCTGACGCTGCTGCTGCAGCAGGTGGACCGCGAGCGACCGCACGTGCGCCGCCGCCGCGG 
  1921 GACATTCAAGCGCAGCAAGCTCCGGGCGCGCGACGGCGGCGAGCGTATCAGCATGCCACT 
  1981 CGACTTCAAGCACCGCATCACCGTGCAGGCCTCACCCGGCCTTGACCGGAGGAGAAACGT 
  2041 CTTCGAGGTCGGGCCTGGGGATTCGCCCACCTTTCCCCGGTTCCGAGCCATCCAGTTGGA 
  2101 GCCTGCAGAGCCAGGCCAGGCATGGGGCCGCCAGTCCCCCCGACGTCTGGAGGACTCAAG  
  2161 CAATGGAGAGCGG CGAGCATGCTGGGCTTGGGGTCCCAGTTCCCCCAAGCCTGGGGAAGC 
  2221 CCAGAATGGGAGGAGAAGGTCCCGCATGGACGAAGCCACATGGTACCTGGATTCAGATGA 
  2281 CTCATCCCCCTTAGGATCTCCTTCCACACCCCCAGCACTCAATGGTAACCCCCCGCGGCC 
  2341 TAGCCTGGAGCCCGAGGAGCCCAAGAGGCCTGTCCCCGCAGAGCGCGGTAGCAGCTCTGG 
  2401 GACGCCCAAGCTGATCCAGCGGGCGCTGCTGCGCGGCACCGCCCTGCTCGCCTCGCTGGG 
  2461 CCTTGGCCGCGACCTGCAGCCGCCGGGAGGCCCAGGACGCGAGCGCGGGGAGTCCCCGAC 
  2521 AACACCCCCCACGCCAACGCCCGCGCCCTGCCCGACCGAGCCGCCCCCTTCCCCGCTCAT 
  2581 CTGCTTCTCGCTCAAGACGCCCGACTCCCCGCCCACTCCTGCACCCCTGTTGCTGGACCT 
 103 
  2641 GGGTATCCCTGTGGGCCAGCGGTCAGCCAAGAGCCCCCGACGTGAGGAGGAGCCCCGCGG 
  2701 AGGCACTGTCTCACCCCCACCGGGGACATCACGCTCTGCTCCTGGCACCCCAGGCACCCC 
  2761 ACGTTCACCACCCCTGGGCCTCATCAGCCGACCTCGGCCCTCGCCCCTTCGCAGCCGCAT 
  2821 TGATCCCTGGAGCTTTGTGTCAGCTGGGCCACGGCCTTCTCCCCTGCCATCACCACAGCC 
  2881 TGCACCCCGCCGAGCACCCTGGACCTTGTTCCCGGACTCAGACCCCTTCTGGGACTCCCC 
  2941 ACCTGCCAACCCCTTCCAGGGGGGCCCCCAGGACTGCAGGGCACAGACCAAAGACATGGG 
  3001 TGCCCAGGCCCCGTGGGTGCCGGAAGCGGGGCCTTGA V e c t o r  
 
AAGGGC TCGAGTCTAGAGGGCCC GCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTC
GATTCTACGCGTACCGGTTAGTAATGAGTTTGGA TTAATTCTGT 
 
Legend: 
 
 
 
 
Clon2F/clon2R
1F1 / clon1R Clon3F/clon3R
Clon4F/clon4R
Clon5F/2725Rv
2725Fw/V5(2)
